Ravi Shankar – Page 815

United Community Banks, Inc. Reports Third Quarter Earnings

Posted on October 20, 2026 by Ravi Shankar

Third Quarter Results Reflect Execution of Significant Strategic Initiatives, Strong Core Loan Growth, and Robust Deposit Growth

GREENVILLE, S.C., Oct. 20, 2026 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NYSE: UCB) (United) today announced financial results for the quarter ended September 30, 2026, which included 9.8% annualized core loan growth, 8.0% annualized core customer deposit growth, and a stable margin following six consecutive quarters of margin expansion.

Chairman and CEO Lynn Harton stated, “Our third quarter results reflect key strategic actions that simplify our balance sheet, reduce risk, and strengthen future operating performance. We completed the acquisition of Peach State Bank on August 1, the sale of our Navitas equipment finance business on September 1, and the restructuring of our investment portfolio in early September. The restructuring shortened duration and significantly improved the yield on our portfolio. At the same time, we achieved high single-digit growth in both core loans and customer deposits in the quarter, reflecting strong momentum resulting from our investment in hiring top talent. New loan production exceeded $1 billion for the second consecutive quarter. The strategies executed in the third quarter position us very well for the future, as demonstrated by improvements in operating return on assets, return on tangible common equity, and operating efficiency ratio.”

In the third quarter, United sold its Navitas equipment finance business for $2.0 billion in cash proceeds, a 7% premium to par. Following the sale, $2.2 billion in held-to-maturity securities were reclassified to available-for-sale designation and long-dated, low yielding securities with an amortized cost basis of $2.5 billion were subsequently sold. The securities repositioning resulted in $2.1 billion of cash proceeds, which, together with the $2.0 billion of Navitas sale proceeds, were redeployed into higher-yielding securities and used to pay down borrowings. Additionally, United completed the acquisition of Peach State Bancshares in the third quarter, increasing density in a dynamic growth market through a complementary, low-risk transaction.

Harton continued, “The actions completed in the third quarter allow us to focus on growing the core banking business within our outstanding Southeast footprint. We believe these actions, including our strong liquidity and capital, position us well for long-term success.”

Third Quarter 2026 Financial Highlights:

EPS of $(1.16) on a GAAP basis and $0.77 on an operating basis, compared to $0.95 and $0.71, respectively, in the second quarter of 2026. GAAP EPS reflects strategic actions executed in the third quarter to improve the long-term company performance, including the completion of the sale of our equipment finance business and repositioning of our investment securities portfolio.
Net loss of $139.7 million reflects strategic actions taken during the third quarter. Adjusting for those items, operating net income was $93.7 million in the third quarter, up 8% from the second quarter.
Total revenue of $(12.0) million resulted from the strategic actions taken in the third quarter. Adjusted for the gain from the sale of Navitas and the loss on the investment portfolio restructuring, which net to $304 million, total operating revenue was $292 million, up from $279 million in the second quarter.
Net interest margin of 3.68% increased by 10 basis points year-over-year and was stable from the second quarter of 2026.
Provision for credit losses totaled $10.0 million, including net charge-offs of $4.0 million, or 0.09% of loans for the third quarter.
- Allowance for credit losses coverage was 1.05% of total loans, up one basis point from June 30, 2026.
Noninterest expense increased $2.3 million on a GAAP basis and decreased $3.3 million on an operating basis, compared to the second quarter.
Third quarter income taxes reflect the specific tax rates applicable to the Navitas sale and investment securities losses, as well as a higher core effective tax rate resulting from higher estimated pre-tax income and certain discrete items recognized in the quarter.
GAAP efficiency ratio is not meaningful due to the securities losses incurred in the third quarter. Operating efficiency ratio improved to 53.1% from 56.7% in the second quarter.
Loan growth of $444 million, or 9.8% annualized, from the second quarter, excluding the impact of Peach State and Navitas.
Customer deposits were up $473 million, or 8.0% annualized, from the second quarter, excluding deposits received from the Peach State acquisition.
Peach State contributed $520 million of loans and $678 million of deposits at the time of the acquisition.
Return on assets was (1.89%) on a GAAP basis and 1.27% on an operating basis. Operating return on assets improved 5 bps from the second quarter.
Return on common equity on a GAAP basis and return on tangible common equity on an operating basis were (14.8%) and 13.9%, respectively.
Repurchased 1.395 million common shares at an average price of $35.81 per share for an aggregate of $50 million in the third quarter. The Board also approved an incremental $100 million share repurchase authorization through the end of 2027, bringing the current outstanding repurchase authorization to $113 million.
Maintained strong capital ratios with preliminary Common Equity Tier 1 of 13.0%.
Quarterly common dividend increased to $0.26 per share declared during the quarter, up 4% year over year.

Year to Date 2026 Financial Highlights:

Net income of $60.2 million, lowered by strategic actions taken in the third quarter. Net income – operating of $265 million, compared with $249 million in 2025.
Diluted earnings per share of $0.49, or $2.18 on an operating basis compared with operating earnings per share of $2.00 in 2025.
Total revenue of $544 million, or $843 million on an operating basis, up 7% from 2025.
Return on assets of 0.28%, or 1.24% on an operating basis up from 1.19% operating return on assets for 2025.
Pre-tax, pre-provision return on assets of 1.76% on an operating basis up from 1.70% operating pre-tax, pre-provision return on assets for 2025.
Return on common equity of 2.18%, or 9.58% on an operating basis compared with 8.92% operating return on common equity for 2025.
Operating return on tangible common equity of 13.3%, up from 12.6% for 2025.

Additional details about the previously announced strategic actions taken in the third quarter are available under “Events and Presentations” in the “News and Events” section of the Investor Relations page on the company’s website, ucbi.com, or directly at https://ir.ucbi.com/events/event-details/strategic-initiatives-conference-call.

Conference Call
United will hold a conference call on Tuesday, October 20, 2026 at 8:30 a.m. ET to discuss the contents of this press release and to share business highlights for the quarter. Participants can pre-register for the conference call by navigating to https://dpregister.com/sreg/10209322/1040c6adc70. Those without internet access or unable to pre-register may dial in by calling 1-844-676-1337. The conference call also will be webcast and may be accessed by selecting “Events and Presentations” under “News and Events” within the Investor Relations section of the company’s website, ucbi.com.

UNITED COMMUNITY BANKS, INC.
Selected Financial Information
*(in thousands, except per share data)*
		2026									2025					Third Quarter 2026 – 2025 Change		For the Nine Months Ended September 30,						YTD 2026 – 2025 Change
	Third Quarter			Second Quarter			First Quarter			Fourth Quarter			Third Quarter			Third Quarter 2026 – 2025 Change			2026			2025		YTD 2026 – 2025 Change
INCOME SUMMARY
Interest revenue	$	362,560		$	344,371		$	333,961		$	346,367		$	353,850				$	1,040,892		$	1,036,572
Interest expense		111,354			103,471			101,197			108,441			120,221					316,022			365,391
Net interest revenue		251,206			240,900			232,764			237,926			233,629		8	%		724,870			671,181		8	%
Noninterest income		(263,172	)		38,380			43,746			40,462			43,219		n/m			(181,046	)		113,583		n/m
Total revenue		(11,966	)		279,280			276,510			278,388			276,848		n/m			543,824			784,764		(31	)
Provision for credit losses		10,013			(29,803	)		10,853			13,662			7,907		n/m			(8,937	)		35,144		n/m
Noninterest expense		162,241			159,915			157,302			152,048			150,868		8			479,458			439,886		9
Income (loss) before income tax expense		(184,220	)		149,168			108,355			112,678			118,073		n/m			73,303			309,734		(76	)
Income tax (benefit) expense		(44,475	)		33,530			24,066			26,223			26,579		n/m			13,121			68,094		(81	)
Net (loss) income		(139,745	)		115,638			84,289			86,455			91,494		n/m			60,182			241,640		(75	)
Non-operating items		310,380			(37,582	)		508			606			3,468					273,306			9,598
Income tax related to non-operating items		(76,932	)		8,347			(113	)		(133	)		(751	)				(68,698	)		(2,079	)
Net income – operating ⁽¹⁾	$	93,703		$	86,403		$	84,684		$	86,928		$	94,211		(1	)	$	264,790		$	249,159		6
Pre-tax pre-provision income ⁽⁵⁾	$	(174,207	)	$	119,365		$	119,208		$	126,340		$	125,980		n/m		$	64,366		$	344,878		(81	)
PERFORMANCE MEASURES
Per common share:
Diluted net income – GAAP	$	(1.16	)	$	0.95		$	0.69		$	0.70		$	0.70		n/m		$	0.49		$	1.91		(74	)
Diluted net income – operating ⁽¹⁾		0.77			0.71			0.70			0.71			0.75		3			2.18			2.00		9
Cash dividends declared		0.26			0.25			0.25			0.25			0.25		4			0.76			0.73		4
Book value		29.27			31.27			30.54			30.17			29.44		(1	)		29.27			29.44		(1	)
Tangible book value ⁽³⁾		20.80			23.31			22.56			22.24			21.59		(4	)		20.80			21.59		(4	)
Key performance ratios:
Return on common equity – GAAP ⁽²⁾⁽⁴⁾		(14.85	)%		12.56	%		9.35	%		9.48	%		9.20	%				2.18	%		8.53	%
Return on common equity – operating ^(1)(2)(4)		9.95			9.39			9.39			9.53			9.83					9.58			8.92
Return on tangible common equity – operating ^(1)(2)(3)(4)		13.90			12.98			13.05			13.31			13.56					13.32			12.57
Return on assets – GAAP ⁽⁴⁾		(1.89	)		1.63			1.22			1.21			1.29					0.28			1.16
Return on assets – operating ⁽¹⁾⁽⁴⁾		1.27			1.22			1.22			1.22			1.33					1.24			1.19
Return on assets – pre-tax pre-provision, excluding non-operating items ⁽^1)(4)(5)		1.84			1.70			1.73			1.78			1.83					1.76			1.70
Net interest margin (fully taxable equivalent) ⁽⁴⁾		3.68			3.68			3.65			3.62			3.58					3.67			3.48
Efficiency ratio – GAAP	n/m				57.01			56.66			54.40			54.30					87.58			55.86
Efficiency ratio – operating ⁽¹⁾		53.11			56.69			55.65			54.19			53.05					55.12			54.64
Equity to total assets		12.14			12.89			12.97			12.99			12.78					12.14			12.78
Tangible common equity to tangible assets ⁽³⁾		8.95			9.94			9.92			9.92			9.71					8.95			9.71
ASSET QUALITY
Nonperforming assets (“NPAs”)	$	81,270		$	103,387		$	98,623		$	93,498		$	97,916		(17	)	$	81,270		$	97,916		(17	)
ACL – funded loans		179,143			168,705			208,396			210,429			215,791		(17	)		179,143			215,791		(17	)
ACL – total		200,237			188,329			225,996			225,520			228,276		(12	)		200,237			228,276		(12	)
Net charge-offs		3,973			7,864			10,377			16,418			7,676		(48	)		22,214			25,508		(13	)
ACL – funded loans to loans		0.94	%		0.94	%		1.06	%		1.09	%		1.13	%				0.94	%		1.13	%
ACL – total to loans		1.05			1.04			1.15			1.16			1.19					1.05			1.19
Net charge-offs to average loans HFI ⁽⁴⁾		0.09			0.16			0.22			0.34			0.16					0.15			0.18
NPAs to total assets		0.28			0.36			0.35			0.33			0.35					0.28			0.35
AT PERIOD END ($ in millions)
Loans held for investment	$	18,988		$	18,024		$	19,602		$	19,384		$	19,175		(1	)	$	18,988		$	19,175		(1	)
Investment securities		6,641			6,377			5,889			5,988			6,163		8			6,641			6,163		8
Total assets		28,882			29,051			28,177			28,003			28,143		3			28,882			28,143		3
Deposits		24,888			23,724			24,025			23,798			24,021		4			24,888			24,021		4
Shareholders’ equity		3,507			3,745			3,655			3,639			3,597		(3	)		3,507			3,597		(3	)
Common shares outstanding (thousands)		119,827			119,764			119,684			120,598			121,553		(1	)		119,827			121,553		(1	)
_{⁽¹⁾ Excludes non-operating items as detailed on Non-GAAP Performance Measures Reconciliation. ⁽²⁾ Net income less preferred stock dividends, divided by average common equity. ⁽³⁾ Excludes effect of acquisition related intangibles and associated amortization. ⁽⁴⁾ Annualized. ⁽⁵⁾ Excludes income tax expense and provision for credit losses.}

UNITED COMMUNITY BANKS, INC.
Loan Portfolio Composition at Period-End
		2026									2025			Linked Quarter Change			Year over Year Change
(in millions)	Third Quarter			Second Quarter			First Quarter			Fourth Quarter		Third Quarter		Linked Quarter Change			Year over Year Change
LOANS BY CATEGORY
Owner occupied commercial RE	$	4,336		$	4,117		$	4,041		$	3,950	$	3,678	$	219		$	658
Income producing commercial RE		5,217			5,018			4,984			5,032		4,534		199			683
Commercial & industrial ⁽¹⁾		2,976			2,859			2,771			2,696		2,593		117			383
Commercial construction & land		1,360			1,143			1,072			998		1,734		217			(374	)
Equipment financing ⁽¹⁾		—			—			1,897			1,848		1,808		—			(1,808	)
Total commercial		13,889			13,137			14,765			14,524		14,347		752			(458	)
Residential mortgage		3,198			3,101			3,122			3,157		3,198		97			—
Home equity		1,504			1,403			1,344			1,319		1,252		101			252
Residential construction & land		211			195			185			191		178		16			33
Consumer		195			193			187			188		192		2			3
Other		(9	)		(5	)		(1	)		5		8		(4	)		(17	)
Total loans held for investment	$	18,988		$	18,024		$	19,602		$	19,384	$	19,175	$	964		$	(187	)

LOANS BY MARKET
Georgia	$	5,336		$	4,662		$	4,617		$	4,635	$	4,584	$	674		$	752
South Carolina		3,180			3,130			3,037			2,971		2,926		50			254
North Carolina		2,786			2,706			2,722			2,712		2,676		80			110
Tennessee		1,979			1,962			1,895			1,913		1,902		17			77
Florida		3,398			3,283			3,229			3,102		3,040		115			358
Alabama		1,114			1,082			1,049			1,050		1,054		32			60
Commercial Banking Solutions ⁽²⁾		1,195			1,199			3,053			3,001		2,993		(4	)		(1,798	)
Total loans held for investment	$	18,988		$	18,024		$	19,602		$	19,384	$	19,175	$	964		$	(187	)
⁽¹⁾ Substantially all equipment financing loans were transferred to held for sale in the second quarter of 2026 as a result of the then-pending sale of Navitas Credit Corp, which subsequently closed on September 1, 2026. Retained equipment financing loans were reclassified to the commercial & industrial line. ⁽²⁾ Reduction in the second quarter of 2026 reflects the transfer of substantially all equipment financing loans to held for sale.

UNITED COMMUNITY BANKS, INC.
Credit Quality
(in thousands)
		2026
	Third Quarter		Second Quarter		First Quarter
NONACCRUAL LOANS
Owner occupied RE	$	12,002	$	20,027	$	18,265
Income producing RE		10,880		11,655		11,037
Commercial & industrial		16,585		21,147		19,890
Commercial construction & land		106		916		17
Equipment financing⁽¹⁾		—		—		8,024
Total commercial		39,573		53,745		57,233
Residential mortgage		31,444		30,506		31,906
Home equity		6,060		6,435		6,209
Residential construction & land		281		338		355
Consumer		962		977		1,009
Total nonaccrual loans held for investment		78,320		92,001		96,712
Equipment finance nonaccrual loans held for sale ⁽¹⁾		—		9,392		—
OREO and repossessed assets		2,950		1,994		1,911
Total NPAs	$	81,270	$	103,387	$	98,623
⁽¹⁾ Substantially all equipment financing loans were transferred to held for sale in the second quarter of 2026 and were subsequently sold in the sale of Navitas Credit Corp. on September 1, 2026. Retained equipment financing loans were reclassified to the commercial & industrial loan category, as equipment financing is no longer an individually significant loan category.

		2026
	Third Quarter					Second Quarter					First Quarter
(in thousands)	Net Charge-Offs			Net Charge-Offs to Average Loans ⁽¹⁾		Net Charge-Offs			Net Charge-Offs to Average Loans ⁽¹⁾		Net Charge-Offs			Net Charge-Offs to Average Loans ⁽¹⁾
NET CHARGE-OFFS (RECOVERIES) BY CATEGORY
Owner occupied RE	$	837		0.08	%	$	(3,447	)	(0.34	)%	$	666		0.07	%
Income producing RE		(17	)	—			57		—			(85	)	(0.01	)
Commercial & industrial		2,281		0.32			6,859		0.97			3,309		0.50
Commercial construction & land		(23	)	(0.01	)		(22	)	(0.01	)		6		—
Equipment financing ⁽²⁾		—		n/m			3,697		0.78			5,835		1.29
Total commercial		3,078		0.09			7,144		0.19			9,731		0.27
Residential mortgage		84		0.01			57		0.01			133		0.02
Home equity		(141	)	(0.04	)		(24	)	(0.01	)		(54	)	(0.02	)
Residential construction & land		107		0.20			(6	)	(0.01	)		12		0.03
Consumer		845		1.73			693		1.47			555		1.21
Total	$	3,973		0.09		$	7,864		0.16		$	10,377		0.22

⁽¹⁾ Annualized. ⁽²⁾ Retained equipment financing loans and related charge-offs were reclassified to the commercial & industrial loan category, as equipment financing is no longer an individually significant loan category.

UNITED COMMUNITY BANKS, INC. Consolidated Balance Sheets(Unaudited)
(in thousands, except share and per share data)	September 30, 2026			December 31, 2025
ASSETS
Cash and due from banks	$	125,069		$	202,586
Interest-bearing deposits in banks		656,536			193,168
Cash and cash equivalents		781,605			395,754
Trading securities		93,760			—
Debt securities available-for-sale		6,546,796			3,750,863
Debt securities held-to-maturity (fair value $1,918,426 at December 31, 2025)		—			2,237,356
Mortgage loans held for sale		34,493			39,381
Loans held for investment		18,988,195			19,384,317
Less allowance for credit losses – loans		(179,143	)		(210,429	)
Loans, net		18,809,052			19,173,888
Premises and equipment, net		409,533			393,714
Bank-owned life insurance		376,000			364,184
Goodwill and other intangible assets, net		1,026,915			967,882
Other assets		803,883			679,532
Total assets	$	28,882,037		$	28,002,554
LIABILITIES AND SHAREHOLDERS’ EQUITY
Liabilities:
Deposits:
Noninterest-bearing demand	$	6,751,068		$	6,252,252
NOW and interest-bearing demand		5,762,468			5,969,864
Money market		7,376,074			6,696,530
Savings		1,093,655			1,085,331
Time		3,733,490			3,619,189
Brokered		171,102			175,264
Total deposits		24,887,857			23,798,430
Short-term borrowings		—			85,000
Long-term debt		39,686			120,400
Accrued expense and other liabilities		447,187			360,038
Total liabilities		25,374,730			24,363,868
Shareholders’ equity:
Common stock, $1 par value; 200,000,000 shares authorized, 119,827,028 and 120,598,266 shares issued and outstanding, respectively		119,827			120,598
Capital surplus		2,724,987			2,754,399
Retained earnings		882,021			914,261
Accumulated other comprehensive loss		(219,528	)		(150,572	)
Total shareholders’ equity		3,507,307			3,638,686
Total liabilities and shareholders’ equity	$	28,882,037		$	28,002,554

UNITED COMMUNITY BANKS, INC. Consolidated Statements of Income (Unaudited)
	Three Months Ended September 30,					Nine Months Ended September 30,
(in thousands, except per share data)		2026			2025		2026			2025
Interest revenue:
Loans, including fees	$	301,420		$	297,929	$	883,109		$	860,269
Securities:
Taxable		52,839			51,522		141,969			162,885
Tax-exempt		1,540			1,681		4,857			5,030
Other		6,761			2,718		10,957			8,388
Total interest revenue		362,560			353,850		1,040,892			1,036,572

Interest expense:
Deposits:
NOW and interest-bearing demand		27,877			35,050		84,124			109,396
Money market		45,747			50,661		127,596			149,805
Savings		489			641		1,452			2,722
Time		29,485			32,123		86,558			94,622
Deposits		103,598			118,475		299,730			356,545
Short-term borrowings		2,546			25		5,097			1,215
Federal Home Loan Bank advances		4,684			—		8,667			433
Long-term debt		526			1,721		2,528			7,198
Total interest expense		111,354			120,221		316,022			365,391
Net interest revenue		251,206			233,629		724,870			671,181

Noninterest income:
Service charges and fees		11,640			11,400		31,560			31,057
Mortgage loan gains and other related fees		10,714			7,098		25,523			18,590
Wealth management fees		4,897			4,757		14,458			13,622
Net gains from sales of other loans		63,222			2,385		66,062			5,776
Lending and loan servicing fees		3,332			4,235		11,401			12,090
Securities (losses) gains, net		(366,101	)		49		(365,970	)		341
Other		9,124			13,295		35,920			32,107
Total noninterest income		(263,172	)		43,219		(181,046	)		113,583
Total revenue		(11,966	)		276,848		543,824			784,764

Provision for credit losses		10,013			7,907		(8,937	)		35,144

Noninterest expense:
Salaries and employee benefits		96,443			90,667		293,934			261,931
Communications and equipment		14,127			13,937		41,972			40,968
Occupancy		11,184			11,502		34,141			33,366
Advertising and public relations		2,485			2,053		7,590			6,815
Postage, printing and supplies		2,515			2,735		8,016			7,791
Professional fees		7,420			6,282		19,864			17,822
Lending and loan servicing expense		2,231			2,428		7,918			6,745
Outside services – electronic banking		3,849			3,543		10,963			9,876
FDIC assessments and other regulatory charges		4,900			4,846		11,496			14,233
Amortization of intangibles		3,348			3,313		9,349			9,891
Merger-related and other charges		6,509			3,468		8,277			9,598
Other		7,230			6,094		25,938			20,850
Total noninterest expense		162,241			150,868		479,458			439,886
(Loss) income before income taxes		(184,220	)		118,073		73,303			309,734
Income tax (benefit) expense		(44,475	)		26,579		13,121			68,094
Net (loss) income		(139,745	)		91,494		60,182			241,640
Preferred stock dividends and deemed dividend at redemption		—			4,848		—			7,994
Earnings and dividends allocated to participating securities		243			507		639			1,356
Net (loss) income available to common shareholders	$	(139,988	)	$	86,139	$	59,543		$	232,290

Net (loss) income per common share:
Basic	$	(1.16	)	$	0.71	$	0.49		$	1.92
Diluted		(1.16	)		0.70		0.49			1.91
Weighted average common shares outstanding:
Basic		120,456			122,116		120,419			121,186
Diluted		120,456			122,252		120,654			121,303

UNITED COMMUNITY BANKS, INC. Average Consolidated Balance Sheets and Net Interest Analysis For the Three Months Ended September 30,
		2026							2025
*(dollars in thousands, fully taxable equivalent (FTE))*	Average Balance			Interest		Average Rate		Average Balance			Interest		Average Rate
Assets:
Interest-earning assets:
Loans, net of unearned income (FTE) ⁽¹⁾⁽²⁾	$	19,797,609		$	302,229	6.06	%	$	19,010,663		$	297,725	6.21	%
Taxable securities ⁽³⁾		6,318,792			52,839	3.34			6,217,693			51,522	3.31
Tax-exempt securities (FTE) ⁽¹⁾⁽³⁾		259,744			2,052	3.16			351,528			2,249	2.56
Other interest-earning assets		814,949			6,761	3.29			413,678			3,389	3.25
Total interest-earning assets (FTE)		27,191,094			363,881	5.32			25,993,562			354,885	5.42

Noninterest-earning assets:
Allowance for credit losses		(174,371	)						(220,805	)
Cash and due from banks		141,941							206,772
Premises and equipment		409,860							397,490
Other assets ⁽³⁾		1,773,946							1,664,648
Total assets	$	29,342,470						$	28,041,667

Liabilities and Shareholders’ Equity:
Interest-bearing liabilities:
Interest-bearing deposits:
NOW and interest-bearing demand	$	5,673,191			27,877	1.95		$	5,825,997			35,050	2.39
Money market		7,252,005			45,747	2.50			6,907,894			50,661	2.91
Savings		1,096,916			489	0.18			1,107,509			641	0.23
Time		3,717,565			29,060	3.10			3,656,172			31,602	3.43
Brokered time deposits		50,699			425	3.33			50,529			521	4.09
Total interest-bearing deposits		17,790,376			103,598	2.31			17,548,101			118,475	2.68
Federal funds purchased and other borrowings		270,956			2,546	3.73			2,284			25	4.34
Federal Home Loan Bank advances		479,674			4,684	3.87			—			—	—
Long-term debt		33,414			526	6.25			155,197			1,721	4.40
Total borrowed funds		784,044			7,756	3.92			157,481			1,746	4.40
Total interest-bearing liabilities		18,574,420			111,354	2.38			17,705,582			120,221	2.69

Noninterest-bearing liabilities:
Noninterest-bearing deposits		6,594,562							6,366,723
Other liabilities		439,078							334,443
Total liabilities		25,608,060							24,406,748
Shareholders’ equity		3,734,410							3,634,919
Total liabilities and shareholders’ equity	$	29,342,470						$	28,041,667

Net interest revenue (FTE)				$	252,527						$	234,664
Net interest-rate spread (FTE)						2.94	%						2.73	%
Net interest margin (FTE) ⁽⁴⁾						3.68	%						3.58	%
_{⁽¹⁾ Interest revenue on tax-exempt securities and loans includes a taxable-equivalent adjustment to reflect comparable interest on taxable securities and loans. The FTE adjustment totaled $1.32 million and $1.04 million, respectively, for the three months ended September 30, 2026 and 2025. The tax rate used to calculate the adjustment was 25%, reflecting the statutory federal income tax rate and the federal tax adjusted state income tax rate.} _{⁽²⁾ Included in the average balance of loans outstanding are loans on which the accrual of interest has been discontinued.} _{⁽³⁾ Unrealized gains and losses on AFS securities, including those related to the transfer from AFS to HTM have been reclassified to other assets. Pretax unrealized losses of $207 million in 2026 and $223 million in 2025 are included in other assets for purposes of this presentation.} _{⁽⁴⁾ Net interest margin is taxable equivalent net interest revenue divided by average interest-earning assets.}

UNITED COMMUNITY BANKS, INC. Average Consolidated Balance Sheets and Net Interest Analysis For the Nine Months Ended September 30,
		2026							2025
*(dollars in thousands, fully taxable equivalent (FTE))*	Average Balance			Interest		Average Rate		Average Balance			Interest		Average Rate
Assets:
Interest-earning assets:
Loans, net of unearned income (FTE) ⁽¹⁾⁽²⁾	$	19,641,031		$	885,136	6.03	%	$	18,632,384		$	859,678	6.17	%
Taxable securities ⁽³⁾		6,077,529			141,969	3.11			6,480,641			162,885	3.35
Tax-exempt securities (FTE) ⁽¹⁾⁽³⁾		315,238			6,480	2.74			354,115			6,730	2.53
Other interest-earning assets		495,951			10,957	2.95			422,123			10,288	3.26
Total interest-earning assets (FTE)		26,529,749			1,044,542	5.26			25,889,263			1,039,581	5.37

Non-interest-earning assets:
Allowance for loan losses		(200,588	)						(217,050	)
Cash and due from banks		163,633							210,027
Premises and equipment		399,958							397,395
Other assets ⁽³⁾		1,720,642							1,637,493
Total assets	$	28,613,394						$	27,917,128

Liabilities and Shareholders’ Equity:
Interest-bearing liabilities:
Interest-bearing deposits:
NOW and interest-bearing demand	$	5,759,773			84,124	1.95		$	6,002,702			109,396	2.44
Money market		6,956,477			127,596	2.45			6,713,585			149,805	2.98
Savings		1,093,764			1,452	0.18			1,133,078			2,722	0.32
Time		3,677,005			85,198	3.10			3,545,792			93,029	3.51
Brokered time deposits		53,843			1,360	3.38			50,488			1,593	4.22
Total interest-bearing deposits		17,540,862			299,730	2.28			17,445,645			356,545	2.73
Federal funds purchased and other borrowings		182,712			5,097	3.73			29,865			1,215	5.44
Federal Home Loan Bank advances		299,963			8,667	3.86			12,824			433	4.51
Long-term debt		68,443			2,528	4.94			215,440			7,198	4.47
Total borrowed funds		551,118			16,292	3.95			258,129			8,846	4.58
Total interest-bearing liabilities		18,091,980			316,022	2.34			17,703,774			365,391	2.76

Noninterest-bearing liabilities:
Noninterest-bearing deposits		6,428,647							6,304,792
Other liabilities		397,842							350,211
Total liabilities		24,918,469							24,358,777
Shareholders’ equity		3,694,925							3,558,351
Total liabilities and shareholders’ equity	$	28,613,394						$	27,917,128

Net interest revenue (FTE)				$	728,520						$	674,190
Net interest-rate spread (FTE)						2.92	%						2.61	%
Net interest margin (FTE) ⁽⁴⁾						3.67	%						3.48	%
_{⁽¹⁾ Interest revenue on tax-exempt securities and loans includes a taxable-equivalent adjustment to reflect comparable interest on taxable securities and loans. The FTE adjustment totaled $3.65 million and $3.01 million, respectively, for the nine months ended September 30, 2026 and 2025. The tax rate used to calculate the adjustment was 25%, reflecting the statutory federal income tax rate and the federal tax adjusted state income tax rate.} _{⁽²⁾ Included in the average balance of loans outstanding are loans on which the accrual of interest has been discontinued and loans that are held for sale.} _{⁽³⁾ Unrealized gains and losses on AFS securities, including those related to the transfer from AFS to HTM have been reclassified to other assets. Pretax unrealized losses of $192 million in 2026 and $244 million in 2025 are included in other assets for purposes of this presentation.} _{⁽⁴⁾ Net interest margin is taxable equivalent net-interest revenue divided by average interest-earning assets.}

UNITED COMMUNITY BANKS, INC.
Non-GAAP Performance Measures Reconciliation
Selected Financial Information
*(in thousands, except per share data)*
		2026									2025					For the Nine Months Ended September 30,
	Third Quarter			Second Quarter			First Quarter			Fourth Quarter			Third Quarter				2026			2025
Noninterest income reconciliation
Noninterest income (GAAP)	$	(263,172	)	$	38,380		$	43,746		$	40,462		$	43,219		$	(181,046	)	$	113,583
Loss on securities portfolio repositioning		366,101			—			—			—			—			366,101			—
Gain on sale on Navitas		(62,230	)		—			—			—			—			(62,230	)		—
Gain on terminated cash flow hedge		—			—			(5,184	)		—			—			(5,184	)		—
Noninterest income – operating	$	40,699		$	38,380		$	38,562		$	40,462		$	43,219		$	117,641		$	113,583

Total revenue reconciliation
Total revenue (GAAP)	$	(11,966	)	$	279,280		$	276,510		$	278,388		$	276,848		$	543,824		$	784,764
Loss on securities portfolio repositioning		366,101			—			—			—			—			366,101			—
Gain on sale on Navitas		(62,230	)		—			—			—			—			(62,230	)		—
Gain on terminated cash flow hedge		—			—			(5,184	)		—			—			(5,184	)		—
Total revenue – operating	$	291,905		$	279,280		$	271,326		$	278,388		$	276,848		$	842,511		$	784,764

Provision for credit losses reconciliation
Provision for credit losses (GAAP)	$	10,013		$	(29,803	)	$	10,853		$	13,662		$	7,907		$	(8,937	)	$	35,144
Release of ACL on equipment finance loans		—			38,477			—			—			—			38,477			—
Provision for credit losses – operating	$	10,013		$	8,674		$	10,853		$	13,662		$	7,907		$	29,540		$	35,144

Noninterest expense reconciliation
Noninterest expense (GAAP)	$	162,241		$	159,915		$	157,302		$	152,048		$	150,868		$	479,458		$	439,886
Payroll transition bonus		—			—			(6,704	)		—			—			(6,704	)		—
FDIC special assessment accrual reversal		—			—			1,885			—			—			1,885			—
Merger-related and other charges		(6,509	)		(895	)		(873	)		(606	)		(3,468	)		(8,277	)		(9,598	)
Noninterest expense – operating	$	155,732		$	159,020		$	151,610		$	151,442		$	147,400		$	466,362		$	430,288

Net income to operating income reconciliation
Net income (GAAP)	$	(139,745	)	$	115,638		$	84,289		$	86,455		$	91,494		$	60,182		$	241,640
Loss on securities portfolio repositioning		366,101			—			—			—			—			366,101			—
Gain on sale on Navitas		(62,230	)		—			—			—			—			(62,230	)		—
Gain on terminated cash flow hedge		—			—			(5,184	)		—			—			(5,184	)		—
Release of ACL on equipment finance loans		—			(38,477	)		—			—			—			(38,477	)		—
Payroll transition bonus		—			—			6,704			—			—			6,704			—
FDIC special assessment accrual reversal		—			—			(1,885	)		—			—			(1,885	)		—
Merger-related and other charges		6,509			895			873			606			3,468			8,277			9,598
Income tax benefit of non-operating items		(76,932	)		8,347			(113	)		(133	)		(751	)		(68,698	)		(2,079	)
Net income – operating	$	93,703		$	86,403		$	84,684		$	86,928		$	94,211		$	264,790		$	249,159

Net income to pre-tax pre-provision income reconciliation
Net income (GAAP)	$	(139,745	)	$	115,638		$	84,289		$	86,455		$	91,494		$	60,182		$	241,640
Income tax (benefit) expense		(44,475	)		33,530			24,066			26,223			26,579			13,121			68,094
Provision for credit losses		10,013			(29,803	)		10,853			13,662			7,907			(8,937	)		35,144
Pre-tax pre-provision income	$	(174,207	)	$	119,365		$	119,208		$	126,340		$	125,980		$	64,366		$	344,878

Diluted income per common share reconciliation
Diluted income per common share (GAAP)	$	(1.16	)	$	0.95		$	0.69		$	0.70		$	0.70		$	0.49		$	1.91
Loss on securities portfolio repositioning		2.28			—			—			—			—			2.27			—
Gain on sale on Navitas		(0.39	)		—			—			—			—			(0.39	)		—
Gain on terminated cash flow hedge		—			—			(0.03	)		—			—			(0.03	)		—
Release of ACL on equipment finance loans		—			(0.25	)		—			—			—			(0.25	)		—
Payroll transition bonus		—			—			0.04			—			—			0.04			—
FDIC special assessment accrual reversal		—			—			(0.01	)		—			—			(0.01	)		—
Merger-related and other charges		0.04			0.01			0.01			0.01			0.02			0.06			0.06
Deemed dividend on preferred stock redemption		—			—			—			—			0.03			—			0.03
Diluted income per common share – operating	$	0.77		$	0.71		$	0.70		$	0.71		$	0.75		$	2.18		$	2.00

Book value per common share reconciliation
Book value per common share (GAAP)	$	29.27		$	31.27		$	30.54		$	30.17		$	29.44		$	29.27		$	29.44
Effect of goodwill and other intangibles		(8.47	)		(7.96	)		(7.98	)		(7.93	)		(7.85	)		(8.47	)		(7.85	)
Tangible book value per common share	$	20.80		$	23.31		$	22.56		$	22.24		$	21.59		$	20.80		$	21.59

Return on tangible common equity reconciliation
Return on common equity (GAAP)		(14.85	)%		12.56	%		9.35	%		9.48	%		9.20	%		2.18	%		8.53	%
Loss on securities portfolio repositioning		29.30			—			—			—			—			9.98			—
Gain on sale on Navitas		(5.03	)		—			—			—			—			(1.71	)		—
Gain on terminated cash flow hedge		—			—			(0.45	)		—			—			(0.15	)		—
Release of ACL on equipment finance loans		—			(3.25	)		—			—			—			(1.08	)		—
Payroll transition bonus		—			—			0.58			—			—			0.19			—
FDIC special assessment accrual reversal		—			—			(0.16	)		—			—			(0.05	)		—
Merger-related and other charges		0.53			0.08			0.07			0.05			0.29			0.22			0.27
Deemed dividend on preferred stock redemption		—			—			—			—			0.34			—			0.12
Return on common equity – operating		9.95			9.39			9.39			9.53			9.83			9.58			8.92
Effect of goodwill and other intangibles		3.95			3.59			3.66			3.78			3.73			3.74			3.65
Return on tangible common equity – operating		13.90	%		12.98	%		13.05	%		13.31	%		13.56	%		13.32	%		12.57	%

Return on assets reconciliation
Return on assets (GAAP)		(1.89	)%		1.63	%		1.22	%		1.21	%		1.29	%		0.28	%		1.16	%
Loss on securities portfolio repositioning		3.73			—			—			—			—			1.29			—
Gain on sale on Navitas		(0.64	)		—			—			—			—			(0.22	)		—
Gain on terminated cash flow hedge		—			—			(0.06	)		—			—			(0.02	)		—
Release of ACL on equipment finance loans		—			(0.42	)		—			—			—			(0.14	)		—
Payroll transition bonus		—			—			0.07			—			—			0.02			—
FDIC special assessment accrual reversal		—			—			(0.02	)		—			—			(0.01	)		—
Merger-related and other charges		0.07			0.01			0.01			0.01			0.04			0.04			0.03
Return on assets – operating		1.27	%		1.22	%		1.22	%		1.22	%		1.33	%		1.24	%		1.19	%

Return on assets to return on assets- pre-tax pre-provision reconciliation
Return on assets (GAAP)		(1.89	)%		1.63	%		1.22	%		1.21	%		1.29	%		0.28	%		1.16	%
Income tax expense		(0.60	)		0.47			0.35			0.37			0.38			0.06			0.33
Provision for credit losses		0.14			(0.42	)		0.16			0.19			0.11			(0.04	)		0.17
Loss on securities portfolio repositioning		4.95			—			—			—			—			1.71			—
Gain on sale on Navitas		(0.84	)		—			—			—			—			(0.29	)		—
Gain on terminated cash flow hedge		—			—			(0.08	)		—			—			(0.02	)		—
Payroll transition bonus		—			—			0.10			—			—			0.03			—
FDIC special assessment accrual reversal		—			—			(0.03	)		—			—			(0.01	)		—
Merger-related and other charges		0.08			0.02			0.01			0.01			0.05			0.04			0.04
Return on assets – pre-tax pre-provision – operating		1.84	%		1.70	%		1.73	%		1.78	%		1.83	%		1.76	%		1.70	%

Efficiency ratio reconciliation
Efficiency ratio (GAAP)	n/m				57.01	%		56.66	%		54.40	%		54.30	%		87.58	%		55.86	%
Loss on securities portfolio repositioning	n/m				—			—			—			—			(35.09	)		—
Gain on sale on Navitas	n/m				—			—			—			—			3.84			—
Gain on terminated cash flow hedge		—			—			1.03			—			—			0.35			—
Payroll transition bonus		—			—			(2.41	)		—			—			(0.79	)		—
FDIC special assessment accrual reversal		—			—			0.68			—			—			0.22			—
Merger-related and other charges		(2.22	)		(0.32	)		(0.31	)		(0.21	)		(1.25	)		(0.99	)		(1.22	)
Efficiency ratio – operating		53.11	%		56.69	%		55.65	%		54.19	%		53.05	%		55.12	%		54.64	%

Tangible common equity to tangible assets reconciliation
Equity to total assets (GAAP)		12.14	%		12.89	%		12.97	%		12.99	%		12.78	%		12.14	%		12.78	%
Effect of goodwill and other intangibles		(3.19	)		(2.95	)		(3.05	)		(3.07	)		(3.07	)		(3.19	)		(3.07	)
Tangible common equity to tangible assets		8.95	%		9.94	%		9.92	%		9.92	%		9.71	%		8.95	%		9.71	%

About United Community Banks, Inc.
United Community Banks, Inc. (NYSE: UCB) is the financial holding company for United Community Bank (United Community), a top-100 U.S. financial institution committed to building stronger communities and improving the financial health and well-being of its customers. United Community offers a full range of banking, mortgage and wealth management services. As of September 30, 2026, United had $28.9 billion in assets and operated 202 offices across Alabama, Florida, Georgia, North Carolina, South Carolina and Tennessee. The company also manages a nationally recognized SBA lending franchise, extending its reach to businesses across the country. United Community is the most awarded bank in the Southeast for Retail Banking Customer Satisfaction by J.D. Power, earning more awards than any other bank in the region, including recognition in 12 of the last 17 years. The company has also been named one of the “Best Banks to Work For” by American Banker for nine consecutive years. In commercial banking, United Community earned multiple 2026 Greenwich Best Bank awards for Small Business Banking. Forbes has consistently named United Community among the World’s Best and America’s Best Banks. Learn more at ucbi.com.

Non-GAAP Financial Measures
This press release, including the accompanying financial statement tables, contains financial information determined by methods other than in accordance with generally accepted accounting principles, or GAAP. This financial information includes certain operating performance measures, which exclude merger-related and other charges that are not considered part of recurring operations, such as “noninterest income – operating”, “total revenue – operating”, “noninterest expense – operating”, “provision for credit losses – operating”, “operating net income,” “pre-tax, pre-provision income,” “operating net income per diluted common share,” “operating earnings per share,” “tangible book value per common share,” “operating return on common equity,” “operating return on tangible common equity,” “operating return on assets,” “return on assets – pre-tax, pre-provision – operating,” “return on assets – pre-tax, pre-provision,” “operating efficiency ratio,” and “tangible common equity to tangible assets.” These non-GAAP measures are included because United believes they may provide useful supplemental information for evaluating United’s underlying performance trends. These measures should be viewed in addition to, and not as an alternative to or substitute for, measures determined in accordance with GAAP, and are not necessarily comparable to non-GAAP measures that may be presented by other companies. To the extent applicable, reconciliations of these non-GAAP measures to the most directly comparable measures as reported in accordance with GAAP are included with the accompanying financial statement tables.

Caution About Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In general, forward-looking statements usually may be identified through use of words such as “may,” “believe,” “expect,” “anticipate,” “intend,” “will,” “should,” “plan,” “estimate,” “predict,” “continue” and “potential” or the negative of these terms or other comparable terminology. Forward-looking statements are not historical facts and represent management’s beliefs, based upon information available at the time the statements are made, with regard to the matters addressed; they are not guarantees of future performance. Actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. Forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time and could cause actual results or financial condition to differ materially from those expressed in or implied by such statements.

Factors that could cause or contribute to such differences include, but are not limited to general competitive, economic, political, regulatory and market conditions. Further information regarding additional factors which could affect the forward-looking statements contained in this press release can be found in the cautionary language included under the headings “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in United’s Annual Report on Form 10-K for the year ended December 31, 2025, and other documents subsequently filed by United with the United States Securities and Exchange Commission (“SEC”).

Many of these factors are beyond United’s ability to control or predict. If one or more events related to these or other risks or uncertainties materialize, or if the underlying assumptions prove to be incorrect, actual results may differ materially from the forward-looking statements. Accordingly, shareholders and investors should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date of this communication, and United undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for United to predict their occurrence or how they will affect United.

United qualifies all forward-looking statements by these cautionary statements.

For more information:
Tom Speir
Chief Financial Officer
(864) 240-6208
Investor_Relations@ucbi.com

Posted in UncategorizedTagged GlobeNewswire

YYForce AI Humanoid Housekeepers to be trained in Novotel Hotel

Posted on October 20, 2026 by Ravi Shankar

Acquires 20 wearable data collection systems to capture real-world housekeeping tasks to support robot learning and development

SINGAPORE, Oct. 20, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (NASDAQ: YFOR) (“YYForce” or the “Company”), a technology-enabled provider of workforce solutions, integrated facility management and commercial robotics services, today announced the acquisition of 20 wearable data collection systems to support its humanoid robotics development program.

The systems, comprising head-mounted egocentric cameras and synchronized wrist-mounted cameras, are intended to capture first-person views and close-up recordings of human task execution. YYForce plans to deploy the equipment through an initiative with the housekeeping team at Novotel Singapore on Stevens, focusing initially on selected hospitality workflows.

The initiative is designed to build a task-specific dataset documenting how experienced housekeeping personnel perform routine service activities. Following review, annotation and technical processing, the demonstrations are intended to support robot learning research, task development and evaluation, including work involving vision-language-action (VLA) models.

Initial Focus: Housekeeping Demonstrations

Planned data collection will focus on selected tasks, including:

Bed and linen preparation: Bed-making sequences, linen handling and pillow arrangement.
Towel and amenity organization: Towel folding, placement and replenishment of guest-room supplies.
Selected cleaning activities: Surface wiping and handling of cleaning tools and materials.

These demonstrations are intended to capture task sequences, hand-object interactions and variations in real operating environments. Translating human demonstrations into robot capabilities will require additional processing, adaptation to the selected robotic hardware, and controlled testing.

“Access to real operating environments and experienced service teams is an important part of our robotics development strategy,” said Mike Fu, Chief Executive Officer of YYForce. “This initiative will help us document how housekeeping tasks are performed in practice and assess how those demonstrations can support humanoid robot learning. Our focus is on building useful datasets, validating individual tasks and progressing toward practical applications in hospitality and facility services.”

Supporting YYForce’s Workforce and Robotics Strategy

The initiative supports YYForce’s broader strategy of combining workforce expertise, facility management operations and robotics to develop technology-enabled service delivery.

The planned development process includes reviewing recordings for quality, annotating selected tasks, preparing suitable training datasets and evaluating whether the demonstrations improve performance on defined robotic tasks. Initial evaluation will focus on task completion, repeatability and safe execution under controlled conditions.

Data collection is planned to follow agreed hotel operating procedures and applicable data protection requirements. The Company expects that collection arrangements will address participant notification and consent where required, guest privacy, access controls and permitted uses of recorded material before recording begins.

The initiative is a development-stage program. The acquisition of the systems and collection of demonstrations do not, by themselves, establish autonomous humanoid capabilities or readiness for commercial deployment.

About YYForce Inc.

YYForce Inc. (NASDAQ: YFOR) is a technology-enabled provider of workforce solutions and integrated facility management and commercial robotics services. The Company is developing AI-enabled workforce platforms and expanding its commercial robotics capabilities to support customers across hospitality, facilities management and other service industries.

For more information, please visit www.yyforce.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company bases these forward-looking statements on its expectations and projections about future events derived from information currently available to it. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. Forward-looking statements include statements regarding planned equipment deployment, data collection, robotics training, technical development and potential commercial applications. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially.

Such risks include equipment performance, data quality and usability, data rights and privacy requirements, collaboration arrangements, technical challenges in transferring human demonstrations to robotic systems, development costs, safety validation and commercial adoption, together with other risks described in the Company’s filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in its most recent annual report. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. YYForce undertakes no obligation to update these statements except as required by law.

Investor Contact
Jason Zhi Yong Phua, Chief Financial Officer
YYForce Inc.
enquiries@yyforce.ai

Investor Relations Contact
Piacente Financial Communications
yfor@thepiacentegroup.com

Posted in UncategorizedTagged GlobeNewswire

Kane Biotech Signs Distribution Agreement with The Stevens Company

Posted on October 20, 2026 by Ravi Shankar

Expands Kane Biotech’s commercial footprint and access to the revyve^® product line across Canada

WINNIPEG, Manitoba, Oct. 20, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it has signed a non-exclusive distribution agreement with The Stevens Company Limited (“Stevens”) for the resale of Kane Biotech’s Health Canada-licensed revyve^® wound-care products in Canada.

Under the agreement, Stevens will be authorized to purchase and resell revyve Antimicrobial Wound Gel in 1 oz and 3 oz formats and revyve Antimicrobial Wound Gel Spray in the 5 oz format throughout Canada. The agreement is effective October 1, 2026.

The agreement is an important step in Kane Biotech’s Canadian distribution strategy. Stevens supplies hospitals, long-term care homes and community healthcare providers across Canada and has significantly expanded its footprint through strategic acquisitions and partnerships, including Schaan Healthcare Products (SK) and CB Medical (AB) in 2024, followed by the complete integration of TRH Services Inc. in early 2026. This partnership combines Kane’s clinical expertise and relationships with Stevens’ established sales and distribution network to broaden revyve’s reach and make it easier for healthcare providers to source and adopt the products.

“Partnering with Stevens brings together two organizations with strong relationships, deep market experience and a shared commitment to improving access to better wound care solutions across Canada,” said Patti Burke-Martin, Vice President of Business Development, Canada. “By combining our respective networks, expertise and reach, we can accelerate the adoption of revyve while continuing to challenge traditional approaches to wound hygiene and biofilm management with a truly differentiated and disruptive solution.”

^{Health Canada-licensed revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray}

The revyve product line is designed to support wound hygiene by providing a moist wound environment conducive to healing, using antimicrobial technology to help inhibit microbial colonization and facilitating debridement through a moist wound environment.

About The Stevens Company Limited

Owned and operated by six generations of the Stevens family since its original founding in London, England in 1830, The Stevens Company is a 100% Canadian-owned distributor of medical and laboratory supplies. With facilities in Vancouver, Calgary, Saskatoon, Winnipeg, Brampton, Montreal, and Halifax, Stevens provides valuable services to healthcare providers, helping them serve the needs of their patients and clients for nearly 200 years. For more information, visit stevens.ca.

About Kane Biotech Inc. (TSX-V:KNE)

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada licensed. To learn more, visit https://kanebiotech.com/products.

Join Kane’s Distribution List & Social Media:

To stay informed on the latest developments, sign up for the Company’s email distribution list.

Kane Biotech on LinkedIn

Website & Corporate Presentation:

kanebiotech.com

Disrupting Biofilms to Save Limbs and Transform Wound Care

For more information:

Dr. Robert Huizinga	Ray Dupuis
Interim CEO	Chief Financial Officer
Kane Biotech Inc.	Kane Biotech Inc.
rhuizinga@kanebiotech.com	rdupuis@kanebiotech.com
(780) 970-1100	(204) 298-2200

^{Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.}

^{Caution Regarding Forward-Looking Information}

^{This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.}

Posted in UncategorizedTagged GlobeNewswire

Vicor Corporation Reports Results for the Third Quarter Ended September 30, 2026

Posted on October 20, 2026 by Ravi Shankar

ANDOVER, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: VICR) today reported financial results for the third quarter ended September 30, 2026. These results will be discussed at 8:00 a.m. Eastern Time, during management’s quarterly investor conference call. The details for the call are below.

Product and royalty revenues for the third quarter ended September 30, 2026 totaled $197.1 million, a 37.5% sequential increase from $143.4 million in the second quarter of 2026, and increased 78.5% from $110.4 million for the corresponding period a year ago.

Gross margin increased sequentially to $134.7 million for the third quarter of 2026, compared to $83.1 million for the second quarter of 2026, and increased from $63.5 million for the corresponding period a year ago. Gross margin, as a percentage of revenue, increased to 68.3% for the third quarter of 2026, compared to 58.0% for the second quarter of 2026, and increased from 57.5% for the corresponding period a year ago. Operating expenses, including contingency fees to law firms enforcing Vicor IP, increased sequentially to $62.5 million for the third quarter of 2026, compared to $48.2 million for the second quarter of 2026, and increased from $42.6 million for the corresponding period a year ago.

Net income for the third quarter was $63.3 million, or $1.33 per diluted share, compared to net income of $49.8 million, or $1.04 per diluted share, for the second quarter of 2026 and net income of $28.3 million or $0.63 per diluted share, for the corresponding period a year ago.

Cash flow from operations totaled $69.7 million for the third quarter, compared to cash flow from operations of $34.0 million in the second quarter of 2026, and cash flow from operations of $38.5 million for the corresponding period a year ago. Capital expenditures for the third quarter totaled $16.1 million, compared to $11.2 million for the second quarter of 2026 and $4.0 million for the corresponding period a year ago. Cash and cash equivalents as of September 30, 2026 increased 13.1% sequentially to approximately $513.1 million compared to approximately $453.6 million as of June 30, 2026.

Backlog for the third quarter ended September 30, 2026 totaled $406 million, a 7% sequential increase from $380 million at the end of the second quarter of 2026, and increased 166% from $153 million for the corresponding period a year ago.

Commenting on recent developments, CEO Dr. Patrizio Vinciarelli stated: “With the purchase of two additional sites within 30 miles of ChiP Fab-1 in Andover, we will be able to provide a nearly 5X increase in capacity from 3 Fabs, relative to Fab-1. Capacity expansion is necessary in view of demand and industry trends.

Open Compute confirmed the challenges of VRs and IVRs. In addition to infringing patents to 1^st GEN VPD, VRs and IVRs face electrical, mechanical and thermal barriers to escalating AI processor requirements. In private presentations and lab sessions with OEMs and Hyperscalers, we demonstrated the distinct advantages of Vicor’s 2^nd GEN VPD. Participants paid attention, providing positive feedback and interest in engaging. The stage is set for broader adoption of high performance ALL-FPA current multiplier modules which enable 2^nd GEN VPD.

On the licensing front, we granted our first VPD license to an AI OEM at Stage-2 unit royalty rates. Unlicensed OEMs and Hyperscalers may not have realized the implications of importing, or planning to import, computing systems infringing Vicor patents to VPD. The ITC decision to institute an investigation into VPD infringement is catching their attention, prompting inquiries about licenses at royalty rates that strongly favor early adopters.”

For more information on Vicor and its products, please visit the Company’s website at www.vicorpower.com.

Earnings Conference Call

Vicor will be holding its investor conference call today, Tuesday, October 20, 2026 at 8:00 a.m. Eastern Time. Vicor encourages investors and analysts who intend to ask questions via the conference call to register with Notified, the service provider hosting the conference call. Those registering on Notified’s website will receive dial-in info and a unique PIN to join the call as well as an email confirmation with the details. Registration may be completed at any time prior to 8:00 a.m. on October 20, 2026. For those parties interested in listen-only mode, the conference call will be webcast via a link that will be posted on the Investor Relations page of Vicor’s website prior to the conference call. Please access the website at least 15 minutes prior to the conference call to register and, if necessary, download and install any required software. For those who cannot participate in the live conference call, a webcast replay of the conference call will also be available on the Investor Relations page of Vicor’s website.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement in this press release that is not a statement of historical fact is a forward-looking statement, and, the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “assumes,” “may,” “will,” “would,” “should,” “continue,” “prospective,” “project,” and other similar expressions identify forward-looking statements. Forward-looking statements also include statements regarding bookings, shipments, revenue, profitability, targeted markets, increase in manufacturing capacity and utilization thereof, future products and capital resources. These statements are based upon management’s current expectations and estimates as to the prospective events and circumstances that may or may not be within the company’s control and as to which there can be no assurance. Actual results could differ materially from those projected in the forward-looking statements as a result of various factors, including those economic, business, operational and financial considerations set forth in Vicor’s Annual Report on Form 10-K for the year ended December 31, 2025, under Part I, Item I — “Business,” under Part I, Item 1A — “Risk Factors,” under Part I, Item 3 — “Legal Proceedings,” and under Part II, Item 7 — “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The risk factors set forth in the Annual Report on Form 10-K may not be exhaustive. Therefore, the information contained in the Annual Report on Form 10-K should be read together with other reports and documents filed with the Securities and Exchange Commission from time to time, including Forms 10-Q, 8-K and 10-K, which may supplement, modify, supersede or update those risk factors. Vicor does not undertake any obligation to update any forward-looking statements as a result of future events or developments.

Vicor designs, manufactures and markets modular power components and complete power systems based upon a portfolio of patented technologies. Vicor licenses its patents to OEMs and hyper-scalers needing supply chain assurance, flexibility and scalability. Headquartered in Andover, Massachusetts, Vicor modules and power system technology are used in high performance computing, industrial, transportation, aerospace and defense.

For further information contact:

James F. Schmidt, Chief Financial Officer
Office: (978) 470-2900
Email: invrel@vicorpower.com

VICOR CORPORATION

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(Thousands except for per share amounts)

QUARTER ENDED

NINE MONTHS ENDED

(Unaudited)

SEPT 30,

2026

2025

2026

2025

Product revenue

130,501

88,698

341,431

257,597

Royalty revenue

66,613

21,725

112,004

42,840

Total net revenues

197,114

110,423

453,435

300,437

Patent litigation settlement

–

45,000

Total net revenues and patent litigation settlement

197,114

110,423

453,435

345,437

Cost of product revenues

62,434

46,910

173,269

145,431

Gross margin

134,680

63,513

280,166

200,006

Operating expenses:

Selling, general and administrative

38,563

22,747

89,356

75,836

Research and development

23,969

19,859

66,900

58,027

Total operating expenses

62,532

42,606

156,256

133,863

Income from operations

72,148

20,907

123,910

66,143

Other income (expense), net

6,585

2,407

14,149

9,198

Income before income taxes

78,733

23,314

138,059

75,341

Less: Provision (benefit) for income taxes

15,401

(4,988

)

4,265

3,278

Consolidated net income

63,332

28,302

133,794

72,063

Less: Net income attributable to

noncontrolling interest

Net income attributable to

Vicor Corporation

63,321

28,292

133,757

72,023

Net income per share attributable

to Vicor Corporation:

Basic

1.37

0.63

2.92

1.60

Diluted

1.33

0.63

2.81

1.59

Shares outstanding:

Basic

46,129

44,734

45,845

44,986

Diluted

47,609

44,930

47,524

45,167

VICOR CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEET
(Thousands)


	SEPT 30,			DEC 31,
	2026			2025
	(Unaudited)			(Unaudited)
Assets

Current assets:
Cash and cash equivalents	$	513,137		$	402,805
Accounts receivable, net		122,488			60,716
Inventories		110,922			91,340
Other current assets		13,594			32,502
Total current assets		760,141			587,363

Long-term deferred tax assets		23,439			27,463
Long-term investment, net		–			2,462
Property, plant and equipment, net		177,987			147,690
Other assets		20,053			20,853

Total assets	$	981,620		$	785,831

Liabilities and Equity

Current liabilities:
Accounts payable	$	24,334		$	12,290
Accrued compensation and benefits		14,047			12,031
Accrued expenses		22,223			3,691
Accrued litigation		–			28,275
Sales allowances		3,512			3,136
Short-term lease liabilities		1,733			1,568
Income taxes payable		208			904
Short-term deferred revenue and customer prepayments		418			3,426

Total current liabilities		66,475			65,321

Long-term income taxes payable		3,143			3,086
Long-term lease liabilities		5,427			5,608
Total liabilities		75,045			74,015

Equity:
Vicor Corporation stockholders’ equity:
Capital stock		518,247			462,805
Retained earnings		555,116			421,359
Accumulated other comprehensive loss		(1,174	)		(1,672	)
Treasury stock		(165,909	)		(170,935	)
Total Vicor Corporation stockholders’ equity		906,280			711,557
Noncontrolling interest		295			259
Total equity		906,575			711,816

Total liabilities and equity	$	981,620		$	785,831

Posted in UncategorizedTagged GlobeNewswire

Matternet Expands NHS Drone Delivery Network to Great Ormond Street Hospital

Posted on October 20, 2026 by Ravi Shankar

The expansion, launched in partnership with Apian, will help provide faster pediatric care for one of the world’s leading children’s hospitals

MOUNTAIN VIEW, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Matternet, Inc. (OTCQB: MTTN) (“Matternet” or the “Company”), a leading developer of autonomous drone networks for ultra-fast, low-cost and zero-emissions delivery, today announced the expansion of its NHS drone delivery network in the U.K. In partnership with Apian, a British startup that has pioneered autonomous logistics with the NHS, the Company commenced drone delivery operations at Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH). Matternet’s drones transport time-sensitive pediatric pathology samples for GOSH, reducing urgent delivery times by up to 90%.

The service will initially connect GOSH with nearby laboratories operated by The Doctors Laboratory (TDL), with plans to expand across the network to additional sites. This rollout builds on Matternet’s decade of operational healthcare experience and highlights the immediate benefits NHS drone delivery brings to patients.

“Children come to Great Ormond Street from all over the country, many of them with rare and complex conditions. For their families, the wait for a test result can be one of the hardest parts of being in hospital,” said Dr Tim Liversedge, Chief of Staff for Core Clinical Services and Consultant Paediatric Anaesthetist at Great Ormond Street Hospital. “Our ambition with this partnership is to support our clinical teams to transport and test samples faster, helping us make the right decisions for our patients and their families as efficiently as possible.”

“Matternet is proud to deliver urgent medical payloads for GOSH, which has long been a world leader in pediatric healthcare,” said Andreas Raptopoulos, founder and CEO of Matternet. “By using autonomous technology to transport samples faster and more reliably, GOSH clinicians can make faster diagnostic and treatment decisions for their patients. We look forward to our continued expansion with Apian to serve more patients across the NHS system.”

“Great Ormond Street Hospital cares for some of the most seriously ill children in the UK, and our clinicians shouldn’t have to wait on London traffic for answers,” said Dr Kimberly Gilmour, Chief of Laboratory Medicine at GOSH. “When samples reach the laboratory in minutes, we can begin testing sooner and get results back to the teams caring for these children. It is an important step towards a delivery network that could serve the whole NHS.”

About Matternet
Matternet is a leading developer of commercial drone delivery systems for urban and suburban environments. The Company builds the Matternet M2 drone, the Matternet Station, and the Matternet Software Platform, and operates its technology directly for customers or in partnership with logistics organizations such as UPS and, in the U.K., Apian. Matternet recently unveiled M3, its next-generation autonomous drone delivery platform. Matternet has achieved many industry firsts, including being the first company authorized for commercial Beyond Visual Line of Sight (BVLOS) drone delivery operations over cities in Switzerland, the first to launch routine revenue-generating drone delivery operations in the U.S., and the first to achieve standard Type Certification and Production Certification from the U.S. Federal Aviation Administration (FAA). Matternet is partnered with UPS and Ameriflight for operations under Part 135 in the U.S., and holds operational approvals from the U.K. Civil Aviation Authority (CAA) for its NHS drone delivery network in London. Matternet has operated commercially for more than a decade, beginning with humanitarian drone delivery missions in 2014, launching B2B healthcare operations in Europe in 2017 and the U.S. in 2019, expanding into B2C drone delivery operations in Silicon Valley in 2024, and launching U.K. operations in 2026. To date, Matternet’s technology has enabled more than 60,000 commercial flights across dense urban and suburban environments in the U.S., Europe and the U.K.

Additional information about Matternet, including Securities and Exchange Commission (SEC) filings and investor materials, is available at investor.matternet.com.

About Apian
Apian is a healthcare logistics company founded by NHS doctors. Its orchestration platform connects hospitals, laboratories and pharmacies through a combination of autonomous drones, ground robotics and software, and already operates a live NHS drone delivery network across London. Apian’s services have delivered thousands of patient samples while reducing costs and carbon emissions compared with traditional ground couriers. For more information, visit apian.health.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different from expectations. Forward-looking statements relate to, among other things, the Company’s intent to scale its drone delivery system, expand commercial availability across restaurant, retail, healthcare and industrial logistics markets, advance and commercialize its next-generation autonomous delivery platform, the targeted specifications and installation requirements of M3, the expected performance and timing of M3 testing, customer pilots and commercial service, the regulatory approvals required for M3, its plans to scale manufacturing capacity, and its customer and strategic partnerships, as well as other plans, objectives, expectations, business strategy, growth opportunities, market opportunity, commercial expansion, regulatory developments, financing plans, and future operating performance.

Important factors that could cause actual results to differ materially from those expressed or implied include, among others, risks related to the Company’s ability to complete the development, testing and certification of M3, achieve M3’s targeted specifications and performance, scale commercial operations, obtain and maintain regulatory approvals, including site and local approvals for its ground infrastructure, manufacture and deploy its technology at scale, secure customer contracts and partnerships, access capital on acceptable terms to fund its operations and M3 development, compete effectively, and execute its business plan, as well as other factors detailed from time to time in the reports the Company files with the SEC, including the risk factors in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Copies of reports filed with the SEC are posted on the Company’s website and are available without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, the Company disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Contacts
Media: press@matternet.com
Business: business@matternet.com
Investors: investors@matternet.com

Posted in UncategorizedTagged GlobeNewswire

Alternative Ballistics Corporation (OTCQB: ALBC) Announces New Purchase Orders from U.S. Retailer Botach and a New Abu Dhabi Distributor

Posted on October 20, 2026 by Ravi Shankar

Botach becomes the Company’s first online wholesale dealer for The Home Defense^™, further expanding its U.S. retail distribution following its e-commerce launch

International purchase order to support upcoming government evaluation and testing with local authorities in Abu Dhabi

LAS VEGAS, NV, Oct. 20, 2026 (GLOBE NEWSWIRE) — Alternative Ballistics Corporation (OTCQB: ALBC) (“Alternative Ballistics” or the “Company”), a public safety technology company focused on next-generation less-lethal solutions, announces new purchase orders from the Company’s first U.S. online retailer, Botach, and a new distribution partner in Abu Dhabi.

Botach has placed an initial purchase order for The Home Defense^™, the Company’s consumer less-lethal self-defense system, becoming its first online wholesale dealer. Separately, the Company’s Abu Dhabi distribution partner has placed a purchase order for The Alternative® to support upcoming evaluations and testing with local authorities.

Botach Becomes First Online Wholesale Dealer for The Home Defense^™

Botach, a Las Vegas-based online retailer of firearms, tactical gear and public safety equipment, plans to introduce The Home Defense^™ to its customer base through its online platform, supported by marketing and advertising initiatives. Serving law enforcement, military, public safety and civilian customers nationwide, Botach provides Alternative Ballistics with an additional channel to reach U.S. consumers.

The Botach order complements the Company’s recently launched direct-to-consumer e-commerce platform, which has generated initial customer orders from California, Arizona, Kansas and West Virginia, extending its online sales reach beyond its home market of Nevada.

“We are pleased to be working with Botach as they introduce The Home Defense^™ to their established customer base,” said Jason LeBlanc, Chief Operating Officer of Alternative Ballistics. “This initial order represents another step in expanding our U.S. distribution network and reaching a broader audience of consumers seeking less-lethal self-defense solutions. We look forward to supporting Botach’s marketing efforts and believe this relationship has the potential to generate additional orders as awareness and demand for the product grow.”

Abu Dhabi Purchase Order to Support Government Evaluation

The Company has also received a purchase order from its new distributor in Abu Dhabi to support upcoming product evaluations and testing with local authorities. Following previous product demonstrations in Abu Dhabi, the purchased units will allow prospective government and law enforcement end users to assess the capabilities and potential applications of The Alternative^®. These evaluations could support future procurement discussions and additional orders in the Middle East.

Steve Luna, Chief Executive Officer of Alternative Ballistics, commented: “This purchase order represents another positive step in executing our international growth strategy. Our focus has been on building relationships with capable distribution partners who can introduce our technology to the appropriate government and law enforcement decision-makers. While the initial order is intended to support evaluation and testing, we believe these opportunities are an important part of the commercialization process. We are encouraged by the continued engagement from our international partners and remain focused on converting those relationships into commercial activity while expanding our global footprint.”

Jags Gill, Chief Revenue Officer of Alternative Ballistics, added: “This order demonstrates the path we are building with our distribution partners, from demonstration, to evaluation, to purchase order. Our partners have been working to introduce The Alternative^® to agencies in their markets, and Abu Dhabi provides a clear example of how that engagement can progress toward commercial activity. We are sharing this progress across our partner network and believe it provides a useful model as other partners advance their own evaluations and procurement discussions with government and law enforcement agencies.”

Purchase The Home Defense^™

The Home Defense^™ is available for purchase through the following channels:

Alternative Ballistics (Available Now): https://alternativeballistics.com/product/the-home-defense/
Botach (Coming Soon): https://botach.com/

About Alternative Ballistics Corporation

Alternative Ballistics Corporation is a public safety technology company focused on developing patented, less-lethal solutions designed to preserve life, reduce risk, and protect individuals in high-stress situations. The Alternative^® is a patented system intended to bridge the capability gap between traditional less-lethal tools and lethal force by providing a controlled force option designed to de-escalate critical incidents. The Company also offers The Home Defense^™, a consumer-focused version of its technology that is commercially available in the United States through its direct-to-consumer e-commerce platform. The Home Defense^™ is designed to provide individuals with an additional, less-lethal self-defense option intended to help reduce the risk of severe or fatal outcomes in situations where force may be necessary.

Cautionary Note Regarding Forward Looking Statements

This news release and statements of ALBC’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s ability to convert pipeline opportunities into sales; changes in regulatory requirements affecting the Company’s products; international political, economic, and regulatory conditions; the Company’s ability to secure necessary product approvals in foreign jurisdictions; competition in the less-lethal technology market; and the Company’s ability to successfully market and expand distribution of The Home Defense™ product. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review ALBC’s filings with the U.S. Securities and Exchange Commission for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Company Contact:

info@alternativeballistics.com
www.alternativeballistics.com

Investor Relations Contact:

Adam S. Holdsworth
MZ Group – MZ North America
305-341-9451
ALBC@mzgroup.us
www.mzgroup.us

Posted in UncategorizedTagged GlobeNewswire

Chicago Atlantic Real Estate Finance Schedules Third Quarter 2026 Earnings Release and Conference Call Date

Posted on October 20, 2026 by Ravi Shankar

CHICAGO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, announced details for the release of its results for the third quarter ended September 30, 2026.

The Company plans to issue its earnings release and supplemental financial information before the market opens on Tuesday, November 10, 2026. Chicago Atlantic will host a conference call and live audio webcast, both open for the general public to hear, later that day at 9:00 a.m. Eastern Time. The number to call for this interactive teleconference is (833) 630-1956 (international callers: 412-317-1837).

The live audio webcast of the Company’s quarterly conference call will be available online in the Investor Relations section of the Company’s website at www.refi.reit. The online replay will be available approximately one hour after the end of the call and archived for one year.

About Chicago Atlantic Real Estate Finance, Inc.

Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) is a market-leading commercial mortgage REIT utilizing significant real estate, credit and cannabis expertise to originate senior secured loans primarily to state-licensed cannabis operators in limited-license states in the United States. REFI is managed by Chicago Atlantic REIT Manager, LLC, an investment manager focused on the cannabis industry and other niche or underfollowed sectors, please visit https://www.refi.reit/.

Contact:
Tripp Sullivan
Lisa Kampf
SCR Partners
IR@REFI.reit

Posted in UncategorizedTagged GlobeNewswire

Capital City Bank Group, Inc. Reports Third Quarter 2026 Results

Posted on October 20, 2026 by Ravi Shankar

TALLAHASSEE, Fla. , Oct. 20, 2026 (GLOBE NEWSWIRE) — Capital City Bank Group, Inc. (NASDAQ: CCBG) today reported net income attributable to common shareowners of $16.9 million, or $0.99 per diluted share, for the third quarter of 2026 compared to $16.3 million, or $0.95 per diluted share, for the second quarter of 2026, and $16.0 million, or $0.93 per diluted share, for the third quarter of 2025.

Return on Assets was 1.53% and Return on Equity was 11.67% for the third quarter of 2026 compared to 1.48% and 11.38%, respectively, for the second quarter of 2026, and 1.47% and 11.67%, respectively, for the third quarter of 2025.

QUARTER HIGHLIGHTS (3^rd Quarter 2026 versus 2^nd Quarter 2026)

Income Statement

Tax-equivalent net interest income totaled $45.1 million compared to $44.2 million for the prior quarter and reflected one additional calendar day in the third quarter
- Net interest margin increased 7 basis points to 4.42% (earning asset yield increased 4 basis points to 5.15% and cost of funds decreased 2 basis points to 73 basis points)
Credit loss provision decreased $1.0 million – net loan charge-offs of 8 basis points (annualized) of average loans – allowance coverage ratio decreased two basis points to 1.22% at September 30, 2026
Noninterest income decreased $1.2 million, or 5.9%, driven by lower mortgage banking revenues and deposit fees
Noninterest expense decreased $0.3 million, or 0.8%, primarily due to lower compensation expense of $0.2 million

Balance Sheet

Loan balances decreased $10.3 million, or 0.4% (average), and decreased $10.1 million, or 0.4% (end of period)
Improved credit quality – total nonperforming assets of $9.7 million (22 basis points of total assets) at September 30, 2026, a $3.7 million decrease from the prior quarter
Deposit balances decreased $31.2 million, or 0.9% (average), and decreased $54.4 million, or 1.5% (end of period) due to the normal seasonal decrease in our public fund balances
Investment security loss AFS and HTM of 3.2% (after-tax) of book value – total security portfolio duration of 2.6 years
Tangible book value per diluted share (non-GAAP financial measure) increased $0.19, or 0.7%, and reflected the negative impact of higher bond interest rates on our quarter-end AFS fair value AOCI adjustment

“The third quarter delivered strong earnings and solid momentum across our Company,” said William G. Smith, Jr., Chairman and Chief Executive Officer. “Continued net interest margin expansion and improved credit quality contributed meaningfully to our third quarter results. We remain well positioned to build on this momentum and finish the year strong.”

Discussion of Operating Results

Net Interest Income/Net Interest Margin

Tax-equivalent net interest income for the third quarter of 2026 totaled $45.1 million, compared to $44.2 million for the second quarter of 2026, and $43.6 million for the third quarter of 2025. Compared to the second quarter of 2026, the increase was primarily attributable to higher income from investment securities and loan interest income, in addition to lower deposit interest expense, partially offset by lower overnight funds income due to lower average balances. The increase in investment securities income reflected new investment purchases at higher rates and higher balances as we deploy additional liquidity into the investment security portfolio. The decrease in deposit interest expense was primarily driven by lower average balances on seasonal public funds accounts and lower rates on time deposits. One additional calendar day also contributed to the increase over the second quarter of 2026. The increase over the third quarter of 2025 was also driven by the same aforementioned factors.

For the first nine months of 2026, tax-equivalent net interest income totaled $132.2 million compared to $128.4 million for the same period of 2025. The increase was primarily attributable to higher investment securities income and lower deposit interest expense, partially offset by lower loan interest income and overnight funds income. New investment purchases at higher yields and higher balances drove the increase in investment securities income. The decrease in deposit interest expense was primarily attributable to lower rates across several product lines. Lower average loan balances contributed to the decrease in loan interest income, while the decrease in overnight funds income reflected the deployment of more liquidity into the investment portfolio as well as a lower average overnight funds rate.

Our net interest margin for the third quarter of 2026 was 4.42%, an increase of seven basis points over the second quarter of 2026 and an increase of eight basis points over the third quarter of 2025. For the first nine months of 2026, our net interest margin increased by six basis points to 4.34% compared to the same period of 2025. The increase in net interest margin over all prior periods was largely attributable to higher investment security yield driven by new purchases at higher rates and lower deposit costs. For the third quarter of 2026, our cost of funds was 73 basis points, a decrease of two basis points from the second quarter of 2026 and five basis points from the third quarter of 2025. Our cost of deposits (including noninterest bearing accounts) was 74 basis points, 76 basis points, and 80 basis points, respectively, for the same periods.

Provision for Credit Losses

We recorded a provision benefit for credit losses of $0.1 million for the third quarter of 2026, compared to a provision expense of $0.9 million for the second quarter of 2026 and $1.9 million for the third quarter of 2025. For the first nine months of 2026, we recorded a provision expense for credit losses of $1.6 million compared to $3.3 million for the same period of 2025. Activity within the components of the provision (loans held for investment (“HFI”) and unfunded loan commitments) for each reported period is provided in the table on page 10. We discuss the various factors that impacted our provision expense for Loans HFI in further detail below under the heading Allowance for Credit Losses.

Noninterest Income and Noninterest Expense

Noninterest income for the third quarter of 2026 totaled $19.4 million, a $1.2 million, or 5.9%, decrease from the second quarter of 2026 and a $2.9 million, or 13.2%, decrease from the third quarter of 2025. The decrease from the second quarter of 2026 was attributable to decreases in mortgage banking revenues of $1.0 million, deposit fees of $0.5 million and other income of $0.2 million partially offset by a $0.5 million increase in wealth management fees. The decrease in mortgage banking revenues was primarily due to lower production volume and the decrease in deposit fees reflected lower overdraft fees attributable to processing changes that better align with industry practices. The increase in wealth management fees was primarily due to higher retail brokerage fees.

The decrease from the third quarter of 2025 was driven by decreases in mortgage banking revenues of $1.1 million, deposit fees of $0.7 million, other income of $0.7 million and wealth management fees of $0.5 million, partially offset by an increase in bank card fees of $0.1 million. The decrease in mortgage banking revenues was due to lower production volume and gain on sale margin. The decrease in deposit fees reflected lower overdraft fees. The decrease in other income reflected a $0.7 million gain from the sale of our insurance subsidiary in the third quarter of 2025 – the advisors at this subsidiary also serviced retail brokerage clients which drove the decline in wealth management fees.

For the first nine months of 2026, noninterest income totaled $59.9 million, a $2.3 million, or 3.8%, decrease from the same period of 2025, attributable to decreases in wealth management fees of $3.3 million partially offset by increases in other income of $0.7 million and bank card fees of $0.3 million. The decrease in wealth management fees was attributable to decreases in retail brokerage fees (due to lower assets under management) and lower insurance commissions (attributable to the aforementioned sale of our insurance subsidiary). The increase in other income was primarily attributable to increases in other fees/commissions of $0.3 million and bank owned life insurance income of $0.2 million. The increase in bank card fees reflected higher card volume.

Noninterest expense for the third quarter of 2026 totaled $42.3 million, a $0.3 million, or 0.8%, decrease from the second quarter of 2026 and a $0.6 million, or 1.4%, decrease from the third quarter of 2025. The decrease from the second quarter of 2026 was primarily attributable to decreases in compensation expense of $0.2 million (commission expense) and other expense of $0.1 million. A $0.5 million decrease in other real estate expense that was partially offset by a $0.3 million increase in telephone expense drove the variance in other expense. The decrease from the third quarter of 2025 was also driven by the same aforementioned factors.

For the first nine months of 2026, noninterest expense totaled $126.3 million, a $2.2 million, or 1.7%, increase over the same period of 2025 and reflected increases in other expense of $3.0 million and occupancy expense of $0.8 million partially offset by a $1.6 million decrease in compensation expense. The increase in other expense was primarily due to a $3.9 million increase in ORE expense, reflecting lower gains on property sales compared to the prior year period, which included a significant gain from the sale of our operations center building in the first quarter of 2025. Lower charitable contribution expense of $0.6 million and professional fee expense of $0.6 million partially offset the increase. The increase in occupancy expense reflected higher expense for FF&E maintenance agreements and software licenses. The decrease in compensation expense reflected lower salary expense of $1.1 million and associate benefit expense of $0.5 million. Lower commission expense drove the decline in salary expense and the decrease in associate benefit expense was primarily attributable to lower stock based compensation.

Income Taxes

We realized income tax expense of $5.2 million (effective rate of 23.6%) for the third quarter of 2026, compared to $5.0 million (effective rate of 23.4%) for the second quarter of 2026 and $5.1 million (effective rate of 24.4%) for the third quarter of 2025. For the first nine months of 2026, we realized income tax expense of $15.0 million (effective rate of 23.5%) compared to $15.3 million (effective rate of 24.2%) for the same period of 2025. Tax benefits accrued from a solar tax credit investment in 2026 drove the decrease in our effective tax rate compared to the prior year periods. Absent discrete items or new tax credit investments, we expect our annual effective tax rate to approximate 23-24% for 2026.

Discussion of Financial Condition

Earning Assets

Average earning assets totaled $4.038 billion for the third quarter of 2026, a decrease of $30.6 million, or 0.8%, from the second quarter of 2026, and an increase of $2.4 million, or 0.1% over the fourth quarter of 2025. Compared to the second quarter of 2026, the change in earning asset mix reflected a $27.2 million decrease in overnight funds, a $10.3 million decrease in loans held for investment, and a $3.5 million decrease in loans held for sale (“HFS”), partially offset by a $10.5 million increase in investment securities. Compared to the fourth quarter of 2025, the change reflected a $171.8 million increase in investment securities and a $2.7 million increase in loans HFS, partially offset by a $99.7 million decrease in overnight funds and a $72.5 million decrease in loans held for investment.

Average loans HFI decreased by $10.3 million, or 0.4% from the second quarter of 2026, and decreased by $72.5 million, or 2.8% from the fourth quarter of 2025. Compared to the second quarter of 2026, the decline was primarily attributable to decreases in commercial real estate loans of $8.4 million, residential real estate loans of $4.5 million, and construction loans of $3.7 million, partially offset by increases in consumer loans (primarily indirect auto) of $2.2 million, home equity loans of $2.0 million, and commercial loans of $1.5 million. Compared to the fourth quarter of 2025, the decline was primarily attributable to decreases in residential real estate loans of $35.2 million, commercial real estate loans of $33.0 million, construction loans of $7.8 million, commercial loans of $5.1 million, and consumer loans of $0.7 million, partially offset by increases in home equity loans of $7.9 million.

Loans HFI at September 30, 2026, decreased $10.1 million, or 0.4% from June 30, 2026, and decreased $56.4 million, or 2.2% from December 31, 2025. Compared to June 30, 2026, the decline was primarily attributable to decreases in commercial real estate loans of $14.3 million, commercial loans of $4.4 million, and other loans of $2.3 million, partially offset by increases in residential real estate loans of $5.9 million, consumer loans (primarily indirect auto) of $3.2 million, home equity loans of $1.7 million, and construction loans of $0.2 million. Compared to December 31, 2025, the decline was primarily attributable to decreases in commercial real estate loans of $32.4 million, residential real estate loans of $16.9 million, commercial loans of $12.2 million, and other loans of $4.4 million, partially offset by increases in home equity loans of $5.2 million, construction loans of $2.4 million, and consumer loans (primarily indirect auto) of $1.7 million.

Allowance for Credit Losses

At September 30, 2026, the allowance for credit losses for loans HFI totaled $30.4 million compared to $31.0 million at June 30, 2026 and $31.0 million at December 31, 2025. Activity within the allowance is provided on page 10. The decline in the allowance reflected improved credit quality metrics and a lower level of net loan charge-offs of 8 basis points of average loans for the third quarter of 2026 versus 14 basis points for the second quarter of 2026 and 18 basis points for the third quarter of 2025. Net loan charge-offs for the nine months ended September 30, 2026 were 11 basis points compared to 12 basis points for the same period of 2025. At September 30, 2026, the allowance represented 1.22% of loans HFI compared to 1.24% at June 30, 2026, and 1.22% at December 31, 2025.

Credit Quality

Nonperforming assets (nonaccrual loans and other real estate) totaled $9.7 million at September 30, 2026, compared to $13.4 million at June 30, 2026 and $10.5 million at December 31, 2025. At September 30, 2026, nonperforming assets as a percentage of total assets was 0.22%, compared to 0.30% at June 30, 2026 and 0.24% at December 31, 2025. Nonaccrual loans totaled $7.4 million at September 30, 2026, a $2.7 million decrease from June 30, 2026 and a $1.2 million decrease from December 31, 2025. Other real estate totaled $2.4 million at September 30, 2026, a $1.1 million decrease from June 30, 2026 and a $0.4 million increase over December 31, 2025. Further, classified loans totaled $20.8 million at September 30, 2026, a $9.0 million decrease from June 30, 2026 and a $6.5 million increase over December 31, 2025.

Deposits

Average total deposits were $3.648 billion for the third quarter of 2026, a decrease of $31.2 million, or 0.9%, from the second quarter of 2026, and comparable to the fourth quarter of 2025. Compared to the second quarter of 2026, the decrease was primarily due to lower public funds balances of $63.8 million (primarily NOW accounts) due to the seasonal reduction in those balances, partially offset by higher core account balances of $32.6 million (primarily money market and noninterest bearing checking).

At September 30, 2026, total deposits were $3.667 billion, a decrease of $54.4 million, or 1.5% from June 30, 2026, and an increase of $4.3 million, or 0.1% over December 31, 2025. The decrease from June 30, 2026, was driven by lower public funds balances of $58.3 million (primarily NOW accounts), partially offset by an increase in core deposit balances of $3.9 million (primarily money market accounts). The increase over December 31, 2025 reflected core deposit growth of $155.8 million, partially offset by lower public funds balances of $151.5 million. Total public funds balances were $503.2 million at September 30, 2026, $561.5 million at June 30, 2026, and $654.7 million at December 31, 2025, respectively.

Liquidity

The Bank maintained an average net overnight funds (i.e., deposits with banks plus FED funds sold, less FED funds purchased) sold position of $337.9 million in the third quarter of 2026 compared to $365.1 million in the second quarter of 2026 and $437.5 million in the fourth quarter of 2025. Compared to the second quarter of 2026, the variance reflected lower average deposits and the deployment of excess liquidity into the investment security portfolio. Compared to the fourth quarter of 2025, the variance was driven by the deployment of excess liquidity into the investment security portfolio.

We also view our investment portfolio as a liquidity source as we have the option to pledge securities in our portfolio as collateral for borrowings or deposits and/or to sell selected securities in our portfolio. Our portfolio consists of debt issued by the U.S. Treasury, U.S. governmental agencies, municipal governments, and corporate entities. At September 30, 2026, the weighted-average maturity and duration of our portfolio were 2.98 years and 2.63 years, respectively, and the available-for-sale portfolio had a net unrealized after-tax loss of $23.1 million, or 2.7% of book value.

At September 30, 2026, we had the ability to generate approximately $1.745 billion (excludes overnight funds position of $340 million) in additional liquidity through various sources including various federal funds purchased lines, Federal Home Loan Bank borrowings, the Federal Reserve Discount Window, and brokered deposits.

Capital

Shareowners’ equity was $573.9 million at September 30, 2026, compared to $570.1 million at June 30, 2026, and $552.9 million at December 31, 2025. For the first nine months of 2026, shareowners’ equity was positively impacted by net income of $49.0 million, the issuance of stock of $3.5 million, and stock compensation accretion of $1.5 million. Shareowners’ equity was reduced by common stock dividends of $13.9 million ($0.81 per share), repurchases of our common stock of $2.6 million (63,088 shares), net adjustments totaling $2.5 million related to transactions under our stock-based compensation plans, and an unfavorable net change of $14.0 million in accumulated other comprehensive loss due to an unfavorable fair value mark on investment securities driven by higher bond rates.

At September 30, 2026, our total risk-based capital ratio was 22.99%, compared to 22.35% at June 30, 2026, and 21.45% at December 31, 2025. Our common equity tier 1 capital ratio was 20.43%, 19.80%, and 18.56%, respectively, on these dates. Our leverage ratio was 12.31%, 11.96%, and 11.77%, respectively, on these dates. At September 30, 2026, all our regulatory capital ratios exceeded the thresholds to be designated as “well-capitalized” under the Basel III capital standards. Further, our tangible common equity ratio (non-GAAP financial measure) was 11.25% at September 30, 2026, compared to 11.03% at June 30, 2026, and 10.79% at December 31, 2025. If our unrealized held-to-maturity securities loss of $16.0 million (after-tax) was recognized in accumulated other comprehensive loss, our adjusted tangible capital ratio would be 10.88%.

About Capital City Bank Group, Inc.

Capital City Bank Group, Inc. (NASDAQ: CCBG) is one of the largest publicly traded financial holding companies headquartered in Florida and has approximately $4.4 billion in assets. We provide a full range of banking services, including traditional deposit and credit services, mortgage banking, asset management, trust, merchant services, bankcards, and securities brokerage services. Our bank subsidiary, Capital City Bank, was founded in 1895 and has 62 banking offices and 107 ATMs/ITMs in Florida, Georgia and Alabama. For more information about Capital City Bank Group, Inc., visit https://www.ccbg.com/.

FORWARD-LOOKING STATEMENTS

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The words “may,” “could,” “should,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “target,” “vision,” “goal,” “will,” “project,” “continue,” “outlook,” “approximate,” “seasonal,” “future” and similar expressions are intended to identify forward-looking statements. The following factors, among others, could cause our actual results to differ: the effects of and changes in trade and monetary and fiscal policies and laws, including the interest rate policies of the Federal Reserve Board; inflation, interest rate, market and monetary fluctuations; local, regional, national, and international economic conditions and the impact they may have on us and our clients and our assessment of that impact; supply-demand imbalances and general economic conditions affecting local real estate prices and a general deterioration in commercial real estate market fundamentals; the costs and effects of legal and regulatory developments, the outcomes of legal proceedings or regulatory or other governmental inquiries, the results of regulatory examinations or reviews and the ability to obtain required regulatory approvals; the effect of changes in laws and regulations (including laws and regulations concerning taxes, banking, securities, and insurance) and their application with which we and our subsidiaries must comply; the effect of changes in accounting policies and practices, as may be adopted by the regulatory agencies, as well as other accounting standard setters; the accuracy of our financial statement estimates and assumptions; changes in the financial performance and/or condition of our borrowers; changes in the mix of loan geographies, sectors and types or the level of non-performing assets and charge-offs; changes in estimates of future credit loss reserve requirements based upon the periodic review thereof under relevant regulatory and accounting requirements; changes in our liquidity position; the timely development and acceptance of new products and services and perceived overall value of these products and services by users; changes in consumer spending, borrowing, and saving habits; greater than expected costs or difficulties related to the integration of new products and lines of business; increased competition and its effect on deposit fees; technological changes, including the impact of generative artificial intelligence; the costs and effects of cyber incidents or other failures, interruptions, or security breaches of our systems or those of our customers or third-party providers; dispositions; acquisitions and integration of acquired businesses; impairment of our goodwill or other intangible assets; changes in the reliability of our vendors, internal control systems, or information systems; our ability to increase market share and control expenses; our ability to attract and retain qualified employees; changes in our organization, compensation, and benefit plans; the soundness of other financial institutions; volatility and disruption in national and international financial and commodity markets; changes in the competitive environment in our markets and among banking organizations and other financial service providers; action or inaction by the federal government, including tariffs or trade wars (including potential resulting reduced consumer spending, lower economic growth or recession, reduced demand for U.S. exports, disruptions to supply chains, and decreased demand for other banking products and services), government intervention in the U.S. financial system; policies related to credit card interest rates, and legislative, regulatory or supervisory actions related to so-called “de-banking,” including any new prohibitions, requirements or enforcement priorities that could affect customer relationships, compliance obligations, or operational practices; the effects of natural disasters (including hurricanes), widespread health emergencies (including pandemics), military conflict (including impacts related to the conflicts in the Middle East and resulting disruptions to energy and other commodities markets and supply chains), terrorism, civil unrest, climate change or other geopolitical events; our ability to declare and pay dividends; structural changes in the markets for origination, sale and servicing of residential mortgages; any inability to implement and maintain effective internal control over financial reporting and/or disclosure control; negative publicity and the impact on our reputation; and the limited trading activity and concentration of ownership of our common stock. Additional information regarding these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our other filings with the SEC, which are available at the SEC’s internet site (https://www.sec.gov). Forward-looking statements in this Press Release speak only as of the date of the Press Release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ, except as may be required by law.

USE OF NON-GAAP FINANCIAL MEASURES
Unaudited

We present a tangible common equity ratio and a tangible book value per diluted share that removes the effect of goodwill and other intangibles resulting from merger and acquisition activity. We believe these measures are useful to investors because they allow investors to more easily compare our capital adequacy to other companies in the industry. Non-GAAP financial measures should not be considered alternatives to GAAP-basis financial statements and other bank holding companies may define or calculate these non-GAAP measures or similar measures differently.

The GAAP to non-GAAP reconciliations are provided below.

(Dollars in Thousands, except per share data)		Sep 30, 2026		Jun 30, 2026		Mar 31, 2026		Dec 31, 2025		Sep 30, 2025
Shareowners’ Equity (GAAP)		$	573,862	$	570,095	$	559,912	$	552,851	$	540,635
Less: Goodwill and Other Intangibles (GAAP)			89,095		89,095		89,095		89,095		89,095
Tangible Shareowners’ Equity (non-GAAP)	A		484,767		481,000		470,817		463,756		451,540
Total Assets (GAAP)			4,396,752		4,450,483		4,453,734		4,385,765		4,323,774
Less: Goodwill and Other Intangibles (GAAP)			89,095		89,095		89,095		89,095		89,095
Tangible Assets (non-GAAP)	B	$	4,307,657	$	4,361,388	$	4,364,639	$	4,296,670	$	4,234,679
Tangible Common Equity Ratio (non-GAAP)	A/B		11.25%		11.03%		10.79%		10.79%		10.66%
Actual Diluted Shares Outstanding (GAAP)	C		17,152,603		17,135,824		17,114,954		17,154,586		17,115,336
Tangible Book Value per Diluted Share (non-GAAP)	A/C	$	28.26	$	28.07	$	27.51	$	27.03	$	26.38

CAPITAL CITY BANK GROUP, INC.
EARNINGS HIGHLIGHTS
*Unaudited*

		Three Months Ended						Nine Months Ended
(Dollars in thousands, except per share data)		Sep 30, 2026		Jun 30, 2026		Sep 30, 2025		Sep 30, 2026		Sep 30, 2025
EARNINGS
Net Income Attributable to Common Shareowners	$	16,940	$	16,277	$	15,950	$	49,034	$	47,852
Diluted Net Income Per Share	$	0.99	$	0.95	$	0.93	$	2.86	$	2.80
PERFORMANCE
Return on Average Assets (annualized)		1.53	%	1.48	%	1.47	%	1.49	%	1.47	%
Return on Average Equity (annualized)		11.67		11.38		11.67		11.45		12.12
Net Interest Margin		4.42		4.35		4.34		4.34		4.28
Noninterest Income as % of Operating Revenue		30.10		31.79		33.89		31.22		32.67
Efficiency Ratio		65.63	%	65.76	%	65.09	%	65.76	%	65.11	%
CAPITAL ADEQUACY
Tier 1 Capital		21.74	%	21.10	%	19.33	%	21.74	%	19.33	%
Total Capital		22.99		22.35		20.59		22.99		20.59
Leverage		12.31		11.96		11.64		12.31		11.64
Common Equity Tier 1		20.43		19.80		17.73		20.43		17.73
Tangible Common Equity⁽¹⁾		11.25		11.03		10.66		11.25		10.66
Equity to Assets		13.05	%	12.81	%	12.50	%	13.05	%	12.50	%
ASSET QUALITY
Allowance as % of Non-Performing Loans		412.92	%	309.72	%	368.54	%	412.92	%	368.54	%
Allowance as a % of Loans HFI		1.22		1.24		1.17		1.22		1.17
Net Charge-Offs as % of Average Loans HFI		0.08		0.14		0.18		0.11		0.12
Nonperforming Assets as % of Loans HFI and OREO		0.39		0.54		0.39		0.39		0.39
Nonperforming Assets as % of Total Assets		0.22	%	0.30	%	0.23	%	0.22	%	0.23	%
STOCK PERFORMANCE
High	$	53.60	$	51.04	$	44.69	$	53.60	$	44.69
Low		47.63		42.79		38.00		39.26		32.38
Close	$	48.33	$	49.42	$	41.79	$	48.33	$	41.79
Average Daily Trading Volume		78,025		95,532		42,187		91,046		31,559

⁽¹⁾ Tangible common equity ratio is a non-GAAP financial measure. For additional information, including a reconciliation to GAAP, refer to Page 9.

CAPITAL CITY BANK GROUP, INC.
CONSOLIDATED STATEMENT OF FINANCIAL CONDITION
*Unaudited*

	2026										2025
(Dollars in thousands)	Third Quarter				Second Quarter			First Quarter			Fourth Quarter			Third Quarter
ASSETS
Cash and Due From Banks	$	71,617		$	67,124		$	64,214		$	62,189		$	68,397
Funds Sold and Interest Bearing Deposits		340,015			412,609			424,756			467,782			397,502
Total Cash and Cash Equivalents		411,632			479,733			488,970			529,971			465,899

Investment Securities Available for Sale		862,097			853,608			800,550			643,922			577,333
Investment Securities Held to Maturity		315,142			304,460			353,296			377,446			404,659
Other Equity Securities		3,203			2,068			2,083			2,069			2,145
Total Investment Securities		1,180,442			1,160,136			1,155,929			1,023,437			984,137

Loans Held for Sale (“HFS”):		23,455			34,278			25,088			21,695			24,204

Loans Held for Investment (“HFI”):
Commercial, Financial, & Agricultural		168,144			172,536			170,268			180,341			179,018
Real Estate – Construction		149,335			149,127			156,630			146,920			156,756
Real Estate – Commercial		736,380			750,637			755,800			768,731			785,290
Real Estate – Residential		1,004,083			998,145			998,720			1,020,942			1,037,324
Real Estate – Home Equity		246,120			244,462			243,932			240,897			234,111
Consumer		184,020			180,859			179,515			182,327			185,847
Other Loans		355			2,668			12,347			4,748			2,283
Overdrafts		1,287			1,437			1,192			1,212			1,378
Total Loans Held for Investment		2,489,724			2,499,871			2,518,404			2,546,118			2,582,007
Allowance for Credit Losses		(30,369	)		(31,007	)		(30,999	)		(31,001	)		(30,202	)
Loans Held for Investment, Net		2,459,355			2,468,864			2,487,405			2,515,117			2,551,805

Premises and Equipment, Net		83,257			81,148			77,670			79,457			79,748
Goodwill and Other Intangibles		89,095			89,095			89,095			89,095			89,095
Other Real Estate Owned		2,353			3,424			1,822			1,936			1,831
Other Assets		147,163			133,805			127,755			125,057			127,055
Total Other Assets		321,868			307,472			296,342			295,545			297,729
Total Assets	$	4,396,752		$	4,450,483		$	4,453,734		$	4,385,765		$	4,323,774
LIABILITIES
Deposits:
Noninterest Bearing Deposits	$	1,331,669		$	1,344,694		$	1,299,933		$	1,251,886		$	1,303,786
NOW Accounts		1,248,073			1,282,360			1,309,527			1,322,114			1,222,861
Money Market Accounts		420,163			418,342			432,874			390,888			405,846
Savings Accounts		509,387			511,000			516,149			503,485			500,323
Certificates of Deposit		157,276			164,613			193,134			193,939			182,096
Total Deposits		3,666,568			3,721,009			3,751,617			3,662,312			3,614,912

Repurchase Agreements		7,187			7,420			4,561			22,018			25,629
Other Short-Term Borrowings		31,694			39,487			28,715			28,074			14,615
Subordinated Notes Payable		33,303			33,303			33,303			42,582			42,582
Other Long-Term Borrowings		567			567			680			680			680
Other Liabilities		83,571			78,602			74,946			77,248			84,721
Total Liabilities		3,822,890			3,880,388			3,893,822			3,832,914			3,783,139

SHAREOWNERS’ EQUITY
Common Stock		171			171			171			171			171
Additional Paid-In Capital		41,516			40,821			39,854			41,650			40,067
Retained Earnings		543,611			531,291			519,632			508,443			499,176
Accumulated Other Comprehensive (Loss) Income, Net of Tax		(11,436	)		(2,188	)		255			2,587			1,221
Total Shareowners’ Equity		573,862			570,095			559,912			552,851			540,635
Total Liabilities and Shareowners’ Equity	$	4,396,752		$	4,450,483		$	4,453,734		$	4,385,765		$	4,323,774
OTHER BALANCE SHEET DATA
Earning Assets	$	4,033,636		$	4,106,894		$	4,124,177		$	4,059,032		$	3,987,850
Interest Bearing Liabilities		2,407,650			2,457,092			2,518,943			2,503,780			2,394,632
Book Value Per Diluted Share	$	33.46		$	33.27		$	32.71		$	32.23		$	31.59
Tangible Book Value Per Diluted Share⁽¹⁾		28.26			28.07			27.51			27.03			26.38
Actual Basic Shares Outstanding		17,113			17,111			17,098			17,084			17,069
Actual Diluted Shares Outstanding		17,153			17,136			17,115			17,155			17,115
⁽¹⁾Tangible book value per diluted share is a non-GAAP financial measure. For additional information, including a reconciliation to GAAP, refer to Page 9.

CAPITAL CITY BANK GROUP, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
*Unaudited*

		2026							2025				Nine Months Ended September 30,
(Dollars in thousands, except per share data)		Third Quarter			Second Quarter		First Quarter		Fourth Quarter		Third Quarter		2026		2025
INTEREST INCOME
Loans, including Fees	$	38,652		$	38,212	$	38,254	$	39,565	$	40,279	$	115,118	$	121,629
Investment Securities		10,640			10,260		9,055		7,768		7,188		29,955		19,674
Federal Funds Sold and Interest Bearing Deposits		3,194			3,366		3,711		4,382		3,964		10,271		11,369
Total Interest Income		52,486			51,838		51,020		51,715		51,431		155,344		152,672
INTEREST EXPENSE
Deposits		6,780			6,933		7,395		7,544		7,265		21,108		22,053
Repurchase Agreements		79			61		73		134		158		213		478
Other Short-Term Borrowings		316			349		327		217		58		992		354
Subordinated Notes Payable		293			288		398		451		383		979		1,473
Other Long-Term Borrowings		8			9		10		9		10		27		26
Total Interest Expense		7,476			7,640		8,203		8,355		7,874		23,319		24,384
Net Interest Income		45,010			44,198		42,817		43,360		43,557		132,025		128,288
Provision for Credit Losses		(80	)		919		712		1,995		1,881		1,551		3,269
Net Interest Income after Provision for Credit Losses		45,090			43,279		42,105		41,365		41,676		130,474		125,019
NONINTEREST INCOME
Deposit Fees		5,168			5,656		5,598		5,811		5,877		16,422		16,258
Bank Card Fees		3,830			3,858		3,630		3,684		3,733		11,318		11,021
Wealth Management Fees		4,640			4,185		4,051		4,525		5,173		12,876		16,142
Mortgage Banking Revenues		3,673			4,660		4,252		4,155		4,794		12,585		12,804
Other		2,073			2,240		2,402		1,928		2,754		6,715		6,027
Total Noninterest Income		19,384			20,599		19,933		20,103		22,331		59,916		62,252
NONINTEREST EXPENSE
Compensation		25,620			25,836		25,703		28,384		26,056		77,159		78,794
Occupancy, Net		7,294			7,319		7,083		7,052		7,037		21,696		20,901
Other		9,381			9,485		8,587		7,431		9,823		27,453		24,460
Total Noninterest Expense		42,295			42,640		41,373		42,867		42,916		126,308		124,155
OPERATING PROFIT		22,179			21,238		20,665		18,601		21,091		64,082		63,116
Income Tax Expense		5,239			4,961		4,848		4,896		5,141		15,048		15,264
NET INCOME	$	16,940		$	16,277	$	15,817	$	13,705	$	15,950	$	49,034	$	47,852
PER COMMON SHARE
Basic Net Income	$	0.99		$	0.95	$	0.92	$	0.80	$	0.93	$	2.87	$	2.81
Diluted Net Income		0.99			0.95		0.92		0.80		0.93		2.86		2.80
Cash Dividend	$	0.27		$	0.27	$	0.27	$	0.26	$	0.26	$	0.81	$	0.74
AVERAGE SHARES
Basic		17,113			17,101		17,129		17,070		17,068		17,114		17,050
Diluted		17,152			17,126		17,146		17,140		17,114		17,141		17,083

CAPITAL CITY BANK GROUP, INC.
ALLOWANCE FOR CREDIT LOSSES (“ACL”)
AND CREDIT QUALITY
*Unaudited*

		2026									2025						Nine Months Ended September 30,
(Dollars in thousands, except per share data)		Third Quarter			Second Quarter			First Quarter			Fourth Quarter			Third Quarter			2026			2025
ACL – HELD FOR INVESTMENT LOANS
Balance at Beginning of Period	$	31,007		$	30,999		$	31,001		$	30,202		$	29,862		$	31,001		$	29,251
Provision for Credit Losses		(129	)		904			635			1,984			1,550			1,410			3,351
Net Charge-Offs		509			896			637			1,185			1,210			2,042			2,400
Balance at End of Period	$	30,369		$	31,007		$	30,999		$	31,001		$	30,202		$	30,369		$	30,202
As a % of Loans HFI		1.22%			1.24%			1.23%			1.22%			1.17%			1.22%			1.17%
As a % of Nonperforming Loans		412.92%			309.72%			278.19%			360.69%			368.54%			412.92%			368.54%
ACL – UNFUNDED COMMITMENTS
Balance at Beginning of Period	$	2,197		$	2,189		$	2,107		$	2,095		$	1,738		$	2,107		$	2,155
Provision for Credit Losses		44			8			82			12			357			134			(60	)
Balance at End of Period⁽¹⁾	$	2,241		$	2,197		$	2,189		$	2,107		$	2,095		$	2,241		$	2,095
ACL – DEBT SECURITIES
Provision for Credit Losses	$	5		$	7		$	(5	)	$	(1	)	$	(26	)	$	7		$	(22	)
CHARGE-OFFS
Commercial, Financial and Agricultural	$	251		$	577		$	300		$	167		$	373		$	1,128		$	615
Real Estate – Construction		–			–			–			–			–			–			–
Real Estate – Commercial		–			–			–			4			–			–			–
Real Estate – Residential		9			38			–			67			12			47			69
Real Estate – Home Equity		(7	)		–			13			10			10			6			34
Consumer		825			613			852			925			954			2,290			2,733
Overdrafts		1,058			524			631			670			619			2,213			1,626
Total Charge-Offs	$	2,136		$	1,752		$	1,796		$	1,843		$	1,968		$	5,684		$	5,077
RECOVERIES
Commercial, Financial and Agricultural	$	282		$	65		$	74		$	44		$	95		$	421		$	287
Real Estate – Construction		–			–			–			–			–			–			–
Real Estate – Commercial		7			7			84			29			8			98			17
Real Estate – Residential		163			27			77			8			13			267			197
Real Estate – Home Equity		4			4			10			6			10			18			61
Consumer		401			468			579			246			369			1,448			1,306
Overdrafts		770			285			335			325			263			1,390			809
Total Recoveries	$	1,627		$	856		$	1,159		$	658		$	758		$	3,642		$	2,677
NET CHARGE-OFFS	$	509		$	896		$	637		$	1,185		$	1,210		$	2,042		$	2,400
Net Charge-Offs as a % of Average Loans HFI⁽²⁾		0.08	%		0.14	%		0.10	%		0.18	%		0.18	%		0.11	%		0.12	%
CREDIT QUALITY
Nonaccruing Loans	$	7,355		$	10,011		$	11,143		$	8,595		$	8,195
Other Real Estate Owned		2,353			3,424			1,822			1,936			1,831
Total Nonperforming Assets (“NPAs”)	$	9,708		$	13,435		$	12,965		$	10,531		$	10,026

Past Due Loans 30-89 Days	$	4,187		$	2,680		$	6,643		$	7,017		$	5,468
Classified Loans
Commercial, Financial and Agricultural		407			1,479			1,660			1,650			1,514
Real Estate – Construction		1,013			379			–			–			718
Real Estate – Commercial		13,783			21,638			6,374			5,897			11,745
Real Estate – Residential		3,693			3,825			3,497			3,601			8,348
Real Estate – Home Equity		1,101			1,461			2,003			1,957			3,043
Consumer		820			1,020			1,011			1,229			1,144
Total Classified Loans		20,817			29,802			14,545			14,334			26,512

Nonperforming Loans as a % of Loans HFI		0.30%			0.40%			0.44%			0.34%			0.32%
NPAs as a % of Loans HFI and Other Real Estate		0.39%			0.54%			0.51%			0.41%			0.39%
NPAs as a % of Total Assets		0.22%			0.30%			0.29%			0.24%			0.23%

⁽¹⁾Recorded in other liabilities.
⁽²⁾Annualized.

CAPITAL CITY BANK GROUP, INC.
AVERAGE BALANCE AND INTEREST RATES
*Unaudited*

		Third Quarter 2026							Second Quarter 2026							First Quarter 2026							Fourth Quarter 2025							Third Quarter 2025							September 2026 YTD							September 2025 YTD
(Dollars in thousands)		Average Balance			Interest	Average Rate			Average Balance			Interest	Average Rate			Average Balance			Interest	Average Rate			Average Balance			Interest	Average Rate			Average Balance			Interest	Average Rate			Average Balance			Interest	Average Rate			Average Balance			Interest	Average Rate
ASSETS:
Loans Held for Sale	$	26,993		$	420	6.17	%	$	30,505		$	500	6.57	%	$	24,716		$	404	6.63	%	$	24,261			374	6.11	%	$	25,276		$	425	6.68	%	$	27,413		$	1,324	6.46	%	$	24,226		$	1,390	7.67	%
Loans Held for Investment⁽¹⁾		2,495,535			38,277	6.09			2,505,875			37,751	6.04			2,538,318			37,886	6.05			2,568,073			39,230	6.06			2,606,213			39,894	6.07			2,513,086			113,914	6.06			2,641,346			120,359	6.09

Investment Securities
Taxable Investment Securities		1,176,534			10,629	3.60			1,165,965			10,249	3.52			1,117,505			9,042	3.26			1,004,420			7,756	3.07			992,260			7,175	2.88			1,153,550			29,920	3.46			993,460			19,644	2.64
Tax-Exempt Investment Securities⁽¹⁾		1,349			15	4.39			1,356			15	4.41			1,620			17	4.25			1,620			17	4.30			1,620			18	4.44			1,441			47	4.35			1,313			43	4.43

Total Investment Securities		1,177,883			10,644	3.60			1,167,321			10,264	3.52			1,119,125			9,059	3.26			1,006,040			7,773	3.08			993,880			7,193	2.88			1,154,991			29,967	3.46			994,773			19,687	2.64

Federal Funds Sold and Interest Bearing Deposits		337,862			3,194	3.75			365,126			3,366	3.70			407,679			3,711	3.69			437,536			4,382	3.97			356,161			3,964	4.42			369,967			10,271	3.71			342,094			11,369	4.44

Total Earning Assets		4,038,273		$	52,535	5.15	%		4,068,827		$	51,881	5.11	%		4,089,838		$	51,060	5.06	%		4,035,910		$	51,759	5.08	%		3,981,530		$	51,476	5.12	%		4,065,457		$	155,476	5.11	%		4,002,439		$	152,805	5.10	%

Cash and Due From Banks		70,540							64,337							63,079							67,291							65,085							66,013							68,074
Allowance for Credit Losses		(31,607	)						(31,602	)						(31,545	)						(30,922	)						(30,342	)						(31,585	)						(30,282	)
Other Assets		309,290							305,809							297,532							294,757							301,678							304,254							300,788

Total Assets	$	4,386,496						$	4,407,371						$	4,418,904						$	4,367,036						$	4,317,951						$	4,404,139						$	4,341,019

LIABILITIES:
Noninterest Bearing Deposits	$	1,316,425						$	1,308,276						$	1,282,988						$	1,303,266						$	1,314,560						$	1,302,686						$	1,324,753
NOW Accounts		1,224,587		$	3,804	1.23	%		1,263,616		$	3,938	1.25	%		1,302,894		$	4,221	1.31	%		1,235,961		$	4,055	1.30	%		1,198,124		$	3,782	1.25	%		1,263,412		$	11,963	1.27	%		1,224,402		$	11,386	1.24	%
Money Market Accounts		433,430			1,964	1.80			419,983			1,857	1.77			403,340			1,752	1.76			415,577			1,977	1.89			416,656			2,090	1.99			419,028			5,573	1.78			422,817			6,617	2.09
Savings Accounts		511,313			102	0.08			513,815			100	0.08			509,351			132	0.10			501,080			157	0.12			503,189			159	0.13			511,500			334	0.09			506,255			509	0.13
Time Deposits		161,771			910	2.23			173,086			1,038	2.41			192,443			1,290	2.72			191,626			1,355	2.80			179,802			1,234	2.72			175,655			3,238	2.46			174,418			3,541	2.71
Total Interest Bearing Deposits		2,331,101			6,780	1.15			2,370,500			6,933	1.17			2,408,028			7,395	1.25			2,344,244			7,544	1.28			2,297,771			7,265	1.25			2,369,595			21,108	1.19			2,327,892			22,053	1.27
Total Deposits		3,647,526			6,780	0.74			3,678,776			6,933	0.76			3,691,016			7,395	0.81			3,647,510			7,544	0.82			3,612,331			7,265	0.80			3,672,281			21,108	0.77			3,652,645			22,053	0.81
Repurchase Agreements		14,160			79	2.20			10,917			61	2.24			15,789			73	1.88			20,690			134	2.57			21,966			158	2.86			13,616			213	2.09			24,752			478	2.58
Other Short-Term Borrowings		31,532			316	3.98			33,545			349	4.17			27,836			327	4.76			20,954			217	4.09			12,753			58	1.82			30,984			992	4.28			10,251			354	4.62
Subordinated Notes Payable		33,303			293	3.45			33,303			288	3.42			41,620			398	3.83			42,582			451	4.15			42,582			383	3.52			36,045			979	3.58			49,113			1,473	3.95
Other Long-Term Borrowings		567			8	5.55			660			9	5.78			680			10	5.68			680			9	5.55			681			10	5.55			635			27	5.68			755			26	4.50
Total Interest Bearing Liabilities		2,410,663		$	7,476	1.23	%		2,448,925		$	7,640	1.25	%		2,493,953		$	8,203	1.33	%		2,429,150		$	8,355	1.36	%		2,375,753		$	7,874	1.32	%		2,450,875		$	23,319	1.27	%		2,412,763		$	24,384	1.35	%

Other Liabilities		83,642							76,331							74,300							78,520							85,422							78,126							75,664

Total Liabilities		3,810,730							3,833,532							3,851,241							3,810,936							3,775,735							3,831,687							3,813,180

SHAREOWNERS’ EQUITY:		575,766							573,839							567,663							556,100							542,216							572,452							527,839

Total Liabilities, Temporary Equity and Shareowners’ Equity	$	4,386,496						$	4,407,371						$	4,418,904						$	4,367,036						$	4,317,951						$	4,404,139						$	4,341,019

Interest Rate Spread				$	45,059	3.92	%				$	44,241	3.86	%				$	42,857	3.72	%				$	43,404	3.72	%				$	43,602	3.81	%				$	132,157	3.83	%				$	128,421	3.75	%

Interest Income and Rate Earned⁽¹⁾					52,535	5.15						51,881	5.11						51,060	5.06						51,759	5.08						51,476	5.12						155,476	5.11						152,805	5.10
Interest Expense and Rate Paid⁽²⁾					7,476	0.73						7,640	0.75						8,203	0.81						8,355	0.82						7,874	0.78						23,319	0.77						24,384	0.81

Net Interest Margin				$	45,059	4.42	%				$	44,241	4.35	%				$	42,857	4.24	%				$	43,404	4.26	%				$	43,602	4.34	%				$	132,157	4.34	%				$	128,421	4.28	%

⁽¹⁾Interest and average rates are calculated on a tax-equivalent basis using a 21% Federal tax rate.
⁽²⁾Rate calculated based on average earning assets.

For Information Contact:
Jep Larkin
Executive Vice President and Chief Financial Officer
850.402. 8450

Posted in UncategorizedTagged GlobeNewswire

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Posted on October 20, 2026 by Ravi Shankar

85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026
European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discography
CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment
Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end
$14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial

BROOMFIELD, Colo., Oct. 20, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the Company’s momentum and value-creating priorities for the quarter ended September 30, 2026.

“The third quarter was a strong one for Aclarion, reflecting the growing interest among physicians in what Nociscan can offer their patients with chronic low back pain,” said Brent Ness, Chief Executive Officer of Aclarion. “Scan volumes grew 85% year-over-year and 117% for the first nine months of 2026, and our clinical program is advancing on multiple fronts. The European Spine Journal publication adds to our growing evidence base, and CLARITY is now enrolling at eleven sites under revised criteria designed to accelerate recruitment and strengthen the study’s real-world applicability.”

The letter highlights Aclarion’s continued commercial traction and an expanding clinical evidence base which will be instrumental in supporting reimbursement initiatives in both the United Kingdom and the United States. The CEO update also highlights the Company’s ongoing commitment to the CLARITY clinical trial with updated inclusion/exclusion criteria to accelerate recruitment. In addition, the Company maintained a strong balance sheet with disciplined capital allocation and investments to create sustainable shareholder value.

The full CEO Shareholder Letter is available on the company’s website.

For more News from Aclarion, please visit: Latest News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the $14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial, our continued commercial traction and an expanding clinical evidence base which will be instrumental in supporting reimbursement initiatives in both the United Kingdom and the United States, our expectation that these changes to the CLARITY enrollment criteria will meaningfully improve recruitment, the plan to update shareholders on enrollment progress and anticipated initial readout timing by year-end, and that the overall CLARITY trial duration remains on track. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

Posted in UncategorizedTagged GlobeNewswire

Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026

Posted on October 20, 2026 by Ravi Shankar

Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001

Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in inflammatory bowel disease

Company to host conference call and webcast at 8:00 a.m. EDT

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis (UC). The results were presented earlier today at United European Gastroenterology (UEG) Week in Barcelona, Spain, and will be discussed alongside additional analyses during a conference call and webcast to be hosted by Odyssey.

The completed OD-001 induction analysis comprises all 56 efficacy-evaluable patients. The high correlation between treatment outcomes and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously established clinical proof of concept for OD-001 and provides biological evidence consistent with RIPK2 scaffolding inhibition. Combined with Phase 1 pharmacology data, these findings support 20 mg twice daily (BID) as the projected lowest maximally efficacious dose.

“These new analyses provide compelling evidence of pharmacologic activity at 20 mg BID, including clinical efficacy in patients with severe endoscopic disease and improvements across markers of intestinal and systemic inflammation,” said Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics. “Transcriptomic findings that align with clinical activity and are consistent with RIPK2 scaffolding inhibition reinforce the mechanistic rationale for this approach in inflammatory bowel disease, strengthen our confidence in the treatment activity of OD-001, and support its continued clinical development.”

Key highlights from the induction period data

Induction (Week 12) efficacy: OD-001 met the trial’s primary endpoint of change from baseline in modified Mayo score at the end of induction at Week 12 (mean reduction of 2.4 points across the evaluable population; p<0.001). At this time point, clinical remission, clinical response, and symptomatic remission were 27%, 61%, and 49%, respectively, in the pooled 20 mg BID group (n=41) and 20%, 40%, and 27%, respectively, at 10 mg BID (n=15).
Improvement in validated biomarkers of intestinal and systemic inflammation: In patients treated with 20 mg BID, fecal calprotectin trended lower, hsCRP and circulating neutrophils were significantly decreased, and serum albumin significantly increased—all changes consistent with reduced intestinal and systemic inflammation. The reduction in neutrophils, a RIPK2-expressing cell type implicated in IBD pathogenesis, provides additional mechanistic support.
Rapid onset and deepening symptomatic benefit: Symptomatic remission at 20 mg BID reached 21% at Week 2, increasing throughout the induction period with no plateau observed through Week 12.
Comparable efficacy across prior treatment exposure: After 12 weeks of treatment with OD-001, clinical remission at 20 mg BID was 29% in advanced therapy-naïve (n=28) and 23% in advanced therapy-experienced (n=13) patients.
Clinical activity in patients with most severe endoscopic disease: Clinical remission at Week 12 for patients taking OD-001 at 20 mg BID was 16% in patients with a Mayo Endoscopic Score (MES) of 3 (n=19).

Transcriptomic analyses reinforce OD-001 treatment activity

On-target activity indicative of RIPK2 inhibition: Exploratory analyses of paired colonic biopsies from baseline and Week 12 showed reductions in RIPK2-responsive and downstream inflammatory gene signatures, including IL-23, TNF/NF-κB, TL1A, AP-1 and T-cell-associated pathways, supporting the proposed mechanism of action.
Modulation of fibrosis-associated and epithelial gene signatures: Reductions in fibrosis-associated signatures and increased expression of genes linked to epithelial homeostasis and mucosal healing aligned with clinical outcomes.
Distinct pharmacology relative to approved mechanisms: Exploratory patient-level comparisons with published datasets of approved therapies suggest OD-001 modulates RIPK2-associated pathways beyond general mucosal improvement achieved with other agents, supporting a differentiated mechanism of action and pharmacodynamic profile.

Safety and tolerability

OD-001 was generally well tolerated during the 12-week induction period, with no serious adverse events, serious infections, treatment-related discontinuations, or treatment-emergent liver function abnormalities. As previously reported, three adverse events in the 20 mg BID group were considered drug-related (two fevers and one headache). One Grade 3 anemia event in the 10 mg BID group occurred in a patient with pre-existing anemia, was considered unrelated to treatment, and resolved with iron supplementation without discontinuing OD-001.

Phase 2a clinical trial overview

The Phase 2a trial (NCT06850727) evaluated the efficacy, safety and tolerability of oral OD-001 in patients with moderate-to-severe ulcerative colitis using an open-label, dose-ranging design. The 12-week induction period included 10 mg and 20 mg BID dosing, with change from baseline in the three-component modified Mayo score as the primary endpoint. This open-label trial had no concurrent placebo control, and the data remain subject to change until database lock.

OD-001 advancing into Phase 2b monotherapy and Phase 2a combination trials

Odyssey plans to advance OD-001 into a randomized, placebo-controlled Phase 2b monotherapy trial and a randomized, active-controlled Phase 2a trial evaluating OD-001 plus vedolizumab versus vedolizumab plus placebo. Both studies will be double-blind, with topline induction results expected in the second half of 2027.

Conference call and webcast

Odyssey will host a conference call and webcast today at 8:00 a.m. EDT to discuss the completed Phase 2a induction results, including additional analyses beyond those presented at UEG. The live webcast and accompanying presentation will be available through the Investors section of Odyssey Therapeutics’ website at www.odysseytx.com. A replay will be available following the event.

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.

For more information, please visit http://www.odysseytx.com and follow Odyssey on LinkedIn or X.

Forward-looking statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the interpretation and potential implications of OD-001’s Phase 2a clinical, safety and exploratory transcriptomic results; evidence of treatment activity and RIPK2 inhibition; selection of 20 mg BID for further development; OD-001’s potential efficacy, safety and use as an oral monotherapy, in combination with vedolizumab or for maintenance treatment; and the design, timing and anticipated results of planned Phase 2b monotherapy and Phase 2a combination trials, including expected topline induction results in the second half of 2027.

Forward-looking statements may be identified by words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “goal,” “may,” “plan,” “potential,” “will,” “would” and variations of these words or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect Odyssey’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. These include the inherent limitations of an open-label trial without a concurrent placebo control; potential uncertainty about exploratory transcriptomic findings; the possibility of different outcomes in future trials; clinical, regulatory, competitive and third-party risks; and other factors described under “Risk Factors” in Odyssey’s most recent Form 10-Q and other SEC filings. Forward-looking statements contained in this press release are made as of this date, and Odyssey undertakes no obligation to update these statements except as required by law.

Contacts

Benjamin Navon
Senior Director, Communications
(857) 431-8785

For investors
investors@odysseytx.com

For media
media@odysseytx.com

Posted in UncategorizedTagged GlobeNewswire